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To better understand molecular interactions upon small-molecule binding, three different 
targets (MDH1, CD44, and Cas-3) for intervention in disease states were studied using biophysical 
and structural biology techniques. The detailed findings will hopefully guide future inhibitor design 
to provide better treatment options for individuals suffering from cancer and tauopathies.  
Malate dehydrogenase I (MDH1) is a cytosolic NAD-dependent oxidoreductase that has 
recently garnered attention for supplementing lactate dehydrogenase (LDH) in supplying adequate 
cytosolic NAD levels necessary during rapid cellular growth in cancer progression. The first ever 
human MDH1 crystal structure is described in detail and differences in the active site loop relative 
to MDH2, the mitochondrial isoform, could potentiate selective inhibitor design.  
CD44 is of the family of hyaladherins that is overexpressed in a variety of different cancers. 
Antagonism of CD44-HA interactions should block downstream signaling and therefore inhibit 
cancer development, progression, and metastasis. Three different approaches are discussed in the 
dissertation. The first uses structure-based drug design to link a small-molecule to a saccharide 
portion of HA. Second, SPR was used to quantify binding affinity of a series of modified-HA 
molecules. Finally, biophysical techniques were used to confirm binding of verbascoside to the 
HABD of CD44. 
The Caspases are of the family of endoproteases involved in apoptosis and pyroptosis 
pathways to maintain homeostasis. Caspase-3 was used as a surrogate for Caspase-2 (only Caspase 
to cleave tau at Asp314) to generate co-crystal complexes with a series of pentapeptides. Described 
structures show the binding modality of the pentapeptides and highlight conformational differences 
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1.1 Macromolecule X-Ray Crystallography in Drug Discovery 
1.1.1 Receptor Hypothesis of Drug Action 
Pharmacology as a scientific discipline was born in the mid-19th century with the first 
pharmacology department being established in Buchheim in 1847 to meet the need of 
understanding how therapeutic drugs and poisons produced their effects.1 The inadequacy of 
understanding therapeutic drugs was summed up in Oliver Wendell Holmes’ comment in 1860: 
“… if the whole materia medica as now used could be sunk to the bottom of the sea, it would be 
all the better for mankind – and the worse for the fishes”.2 In 1865, Kekulé discovered the structure 
of the benzene ring and the now familiar 2-dimensional representations of the structure of organic 
molecules began to be defined which paved the way for lock-and-key relationships between drugs 
and their receptors.1 The receptor theory hypothesis was first put forward by John Newport Langley 
in 1905 where he used the term “receptive substance” as distinct from the term “contractile 
substance”.3 The term “receptive substance” was used to explain the actions of nicotine and curare 
on skeletal muscle based on his experiments on salivary secretion in dogs.4 A. V. Hill, a student 
working in Langley’s laboratory, expressed the receptor idea quantitatively in terms of a 
bimolecular reaction following the law of mass action which later became the well-known Hill-
Langmuir equation.5,6 Paul Ehrlich, the father of immunology, through his interest in the 
immunology and chemotherapy of infectious diseases, came to the idea of receptors.7 Bacterial 
toxins interact with nutrient-capturing structures of cells, “sidechains” which he later called 
“receptors”, thus starving the cells which respond by making more of these “sidechains” and 
releasing them into circulation where they combine with the toxin rendering them harmless.8 He 
later postulated that bacterial sidechains and sidechains of the host differ which led him to the 
discovery of Salvarsan in 1909, the first effective treatment for syphilis.9,10 Receptor theory was 
published by Alfred Joseph Clark in his 1933 book, “The Mode of Action of Drugs on Cells” where 
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he calculates for potent drug-like acetylcholine, the number of molecules required to effect a 
cellular response is insufficient to cover the cell and therefore concluded there must be a specific 
receptor interaction at the cell surface that mediate the cellular response.11 
1.1.2 History of X-Ray Crystallography 
The history of X-rays traces back to Germany in 1895, where William Röntgen first 
generated X-rays by means of a discharge from a large induction coil passed through a Hittorf’s 
vacuum tube or through a well-exhausted Crookes’ or Lenard’s tube.12,13 The discharge was found 
to penetrate black cardboard and caused an observed fluorescence still visible at two meters.12,13 In 
his 1895 Science paper, Röntgen describes this fluorescent discharge as “X-rays (as I will call the 
rays, for the sake of brevity)” and qualified the transparency of several different metals and media 
for which he was awarded the Nobel Prize in Physics 1901.12,13 It was 17 years later that Max von 
Laue, with the help of his two assistants, postulated through his work on a blue crystal of copper 
sulfate pentahydrate that the diffraction of X-rays might be related to the interatomic distances.14 
Laue was unable to provide an explanation of the diffraction images, but a father-son duo, Sir 
William Henry Bragg and Sir William Lawrence Bragg, were empirically able to relate diffraction 
patterns to crystal structure.15 William Lawrence Bragg developed a mathematical formula that 
became known as Bragg’s Law, nλ = 2dsinθ, describing the relationship between the angle of 
refraction, the wavelength of radiation, and interplanar spacing in the crystal lattice.15 Constructive 
interference of a diffracted wave will be observed when the distance traveled through the crystal is 
an integer (n) multiple of the wavelength (λ) and that the path length through the crystal is twice 
the interplanar space (d) in the crystal multiplied by the sine of the angle of incidence (θ). The 
formula has withheld the test of time and is paramount to the interpretation of crystallographic 
data.16–19 The elder Bragg, William Henry Bragg, went on to construct the first X-ray 
spectrometer.17 One of the first structures solved by the duo was that of diamond.20 The work of 
Max von Laue, Sir William Henry Bragg and Sir William Lawrence Bragg was immediately 
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recognized by the scientific community with Laue receiving a Nobel Prize in Physics in 1914 and 
both of the Braggs in 1915 (Sir William Lawrence Bragg received the award at 25 and he is still 
the youngest person to win the Nobel Prize in Physics).14 The Nobel Prize in Physics has been 
awarded 23 times for crystallography or for essential technology in how it is used and of the 23 
awards, 12 have been awarded directly for achievement in macromolecule crystallography.14 
1.1.3 X-Ray Diffraction for Determination of Biological Crystals 
The first diffraction image for a biological structure was of pepsin protease generated by J. 
Desmond Bernal and Dorothy Hodgkin (previously Crowfoot) in 1934.21 The diffraction was of 
poor quality as the crystals were mounted on glass fibers and exposed to air as was customary for 
small molecule crystals.21 They therefore decided that crystals needed to be hydrated and therefore 
sealing them in capillaries with a drop of mother liquor could efficiently protect them from 
desiccation. Of the images collected, Bernal noted that: “… the [X-ray] pictures yielded by protein 
crystals were of exceptional perfection. They showed large unit cells with great wealth of 
reflections […] found even at comparatively high angles corresponding to such low spacings as 
2 Å. This indicated that not only were the molecules of the proteins substantially identical in shape 
and size, but also that they had identical and regular internal structures right down to atomic 
dimensions”.22 The structure of the pepsin protease in this form was not determined until 1990 by 
Hodgkin’s former student, Sir Tom Blundell.22 Hodgkin’s impact on biomolecular crystallography 
cannot be understated: she collected the first diffraction images of insulin23, determined the 
structure and stereochemistry of sterols14, showed that penicillin contained a β-lactam ring24, and 
solved the structure of the first organometallic compound, vitamin B12, work for which she was 
awarded the 1964 Nobel Prize in Chemistry.25 The first proteins to have their complete structures 
solved by X-ray crystallography were sperm whale myoglobin, in 1958, and horse hemoglobin, in 
1960.26,27 The structures were solved by Sir John Kendrew and Max Perutz (a pioneer in the 
methodology of protein crystallography especially isomorphous replacement)28, respectively, and 
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only extend to 6 Å resolution. In the two decades following the solving of the myoglobin and 
hemoglobin structures, several protein structures with clinical relevance were published including 
dogfish lactate dehydrogenase29, bacterial thermolysin30, bovine pancreatic phospholipase A231, and 
bacterial dihydrofolate reductase32. The Protein Data Bank was established in 1973 and contained 
nine protein structures, six of which were of interest in drug design, showing the impetus of the 
early stages of structural biology.14,33 The bovine pancreatic trypsin inhibitor, aprotinin, which is 
administered to control bleeding during major surgery, was one the first structures deposited into 
the PDB.34,35 
1.1.4 Application of Structure-Based Drug Design Using 
Crystallography 
Wootton’s work on compounds designed to fit a site in hemoglobin merged the receptor 
theory, a drug molecule interacting with a specific receptor of a complementary structure, with 
structural biology.36 In the study, the known three-dimensional coordinates of hemoglobin with 
2,3-diphosphoglycerate (DPG) were used to generate a molecular model to design compounds 
which should bind to the deoxy conformation and thereby promote oxygen liberation.36 The 
designed compounds, using structural data, were found to promote oxygen liberation and thus mark 
the first known compounds designed using structure-based design.36 The compounds ended up 
proving unsuccessful as no anti-sickling compound ever came to the market. The concept of 
structure-based drug design continued to grow in importance leading to the rational drug design 
cycle being elaborated: a molecule can be designed and optimized using structural data of the 
macromolecule target followed by co-crystallization of the molecule with the target of interest and 
then the cycle can be repeated.37 This cycle is still used in the drug discovery process with additional 
sophistications including experimental confirmation of binding, ADMET evaluation, and 
biological application.38  
The first structure that contributed to the design of a marketed drug was bovine pancreatic 
carboxypeptidase A. The work done by the Lipscomb lab revealed that the preferred substrate of 
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the zinc metalloprotease is the C-terminal residue of a polypeptide chain with a preference for 
aromatic or branched aliphatic sidechains.39 The active site is marked by a deep pocket-like 
topography with the presence of an arginine residue to interact with the free carboxylate, and a 
large mostly hydrophobic pocket to accommodate the P1’ sidechain.39 The arginine when 
interacting with a substrate carboxylate induces a large conformational change in a nearby tyrosine 
that essentially closes the active site.39 This structure-function relationship was used by scientists 
at Squibb to build a model of the active site of angiotensin-converting enzyme (ACE) whose 
function is the cleavage of two C-terminal amino acids from angiotensin I to transform into 
angiotensin II which causes immediate increase in blood pressure.40 The scientist at Squibb used 
the model of carboxypeptidase and the known ACE substrate to design potent inhibitors of ACE 
eventually leading to captopril which came to market in 1981 as the first drug using structure-based 
design.41,42 
1.2 Targets for Cancer Intervention 
Cancer is the second leading cause of death worldwide behind cardiovascular diseases. 
This year, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 
606,520 people will die from the disease.43 The most common cancers are breast cancer, lung and 
bronchus cancer, prostate cancer, and colon and rectum cancer.43 Approximately 39.5% of men and 
women will be diagnosed with cancer at some point during their lifetimes.43 Estimated expenditures 
for cancer care in the United States in 2018 were $150.8 billion and in future years, costs are likely 
to increase as the population ages and more people develop cancers.43 There is a need for novel 
cancer therapeutics to help patients living with cancer while decreasing the cost of cancer care. 
Cancer progression, metastasis, and motility has been extensively studied and characterized. 
Normal cells are tightly regulated by hundreds of genes that intricately control the process of cell 
division.44 Carcinogenesis is started through a variety of environmental and inherited characteristics 
that can cause damage to DNA thus causing mutations in somatic cells.44 These cells can undergo 
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a series of events including activation of growth-promoting oncogenes, impaired apoptosis, and 
inactivation of tumor suppressor genes which can lead to an altered gene product with abnormal 
structural and regulatory proteins which is a hallmark of a malignant tumor.44 Cancer cells are 
characterized by large, variably shaped nuclei, disorganized arrangement, varying size and shape, 
and loss of normal features.44 The role of CD44 and malate dehydrogenase I (MDH1) in cancer 
progression and metastasis will be discussed in detail in the subsequent two sections. 
1.3 CD44 
1.3.1 Role of the Extracellular Matrix in Cancer 
The extracellular matrix (ECM) is the non-cellular space present within all tissues and 
organs that provides the scaffolding for the cellular constituents and initiates biochemical signals 
that play a role in morphogenesis, differentiation, and homeostasis.45 Every tissue has a unique 
ECM composition that arises from tissue development and constant remodeling to maintain 
extracellular homeostasis.45 The ECM is composed of two main classes of macromolecules: fibrous 
proteins and proteoglycans (PGs) which are made up of glycosaminoglycan (GAG) chains linked 
to a protein core (with the exception of hyaluronan).46,47 The ECM is highly charged and hydrated 
and contributes to compression strength and flexibility.48 The biochemical properties of the ECM 
allow for the control of signaling molecules interaction with their cognate receptors.49 ECM 
remodeling is tightly regulated through controlling the expression/activity of ECM enzymes.50,51 
The activities of the remodeling enzymes can be deregulated with senescence and certain disease 
states such as cancer.52 The deregulation of the ECM dynamics leads to disorganization as the 
amount, composition, and/or topography becomes abnormal.52 One of the main contributors to the 
altered activities of ECM remodeling enzymes are cancer-associated fibroblasts (CAFs).53 
Deregulation of the ECM can potentiate oncogenic effects on signaling pathways, malignant cell 
transformations, and increased tissue stiffness which promotes tumor cell invasion and 
progression.52 Proper regulation of the ECM remodeling enzymes could decrease tumor 
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progression and metastasis to different tissues. Targeting abnormal ECM as an effective cancer 
therapeutic requires an understanding of how the ECM is organized and maintained and how it 
becomes deregulated in cancer. 
1.3.2 Hyaluronan: Signaling Molecule of the ECM 
Hyaluronan (HA) is a major component of the ECM where it has been shown to promote 
cell motility, adhesion, and proliferation and thus plays a critical role in wound repair, 
inflammation, and metastasis.54,55 Hyaluronan is a GAG synthesized by a family of three 
transmembrane glycosyltransferases, hyaluronan synthetase 1-3 (HAS1-3).56,57 HAS1-3 are plasma 
membrane bound proteins that can alternatively conjugate (b-1,4)-glucuronic acid (Glc) and (b-
1,4)-N-acetylglucosamine (NaG) to form the polymeric molecule that is extruded into the ECM.56,57 
4-methylumbelliferone blocks HA synthesis through the inhibition of HASs and was found to cause 
tumor suppression in breast cancer cell lines.58 Inhibition of HASs is not a focus of this thesis but 
highlights the importance of hyaluronan in the extracellular matrix and cancer. Under physiological 
conditions, HA exists as a high-molecular weight polymer >106 Da where it regulates a variety of 
cell behaviors, including cell adhesion, motility, and growth.59–63 HA levels are tightly regulated to 
maintain homeostasis and approximately 30% of circulating HA is degraded and replaced by newly 
formed HA every 24 hours.64 Degradation of HA occurs by endocytic uptake which is triggered by 
binding to CD44 and/or lymphatic vessel endothelial receptor-1 (LYVE-1).65,66 Hyaluronidases 
(HYAL) degrade HA to oligosaccharides which are then digested by glucuronidase and 
hexosaminidase to yield more supply of Glc and NaG, respectively, that can be reused by HASs to 
form new HA molecules.67,68 Degradation of HA is increased by reactive oxygen species and 
pathological conditions such as cancer.69,70 HA fragments, <5 x 105 Da, generated during 
inflammation/tumorigenesis/tissue injury can act as a signaling molecule by alerting the injured 
host that HA homeostasis has been affected.69–71 Degradation of HMW-HA to HA fragments has 
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been linked to cell differentiation72, angiogenesis73, tumorigenesis74, and resistance to cancer 
chemotherapy75. 
1.3.3 Hyaladherin Family of Proteins 
The diverse roles of HA, described in the previous section, are mediated through 
hyaladherins, or hyaluronan-binding proteins (HABPs).76,77 Of the HABPs, CD44 and RHAMM 
(receptor for hyaluronic-acid-mediated motility) are signal-transducing receptors that influence cell 
proliferation, survival and motility.76,77 Cellular responses resulting from interactions of HA with 
CD44 and RHAMM involve tyrosine kinases, protein kinase C, focal adhesion kinase (FAK), 
phosphatidylinonsitol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), nuclear factor-
kB and Ras, as well as cytoskeletal components.76,78–80 The hyaladherins can be localized on cell 
membranes (such as LYVE-1 and CD44) or can be in the ECM or cytoplasm (such as TSG-6 and 
RHAMM).77 As discussed previously, various lengths of HA can trigger diverse biological 
responses because of recognition with a variety of hyaladherins.71 Many of the HABPs contain a 
common structural domain termed a Link module that is involved in hyaluronan binding.77 The 
Link module was first characterized in the link protein isolated from cartillage.81 The Link module 
can be subdivided into three groups based on the size of the binding domain: Type A consists of a 
single Link module, e.g., TSG-6; Type B consists of a Link module with N- and C-terminal 
extensions, e.g., CD44; and Type C consists of a Link module pair, e.g., Link protein.82 The 
consensus fold of the Link module is two a-helices and two triple-stranded anti-parallel b-sheets. 
A BX7B motif, where B corresponds to an arginine or lysine residue and X is any non-acidic amino 
acid, has been implicated in binding of hyaluronan in hyaladherins regardless of the presence of 
the Link module.83 Selectively targeting a hyaluronan binding domain of a hyaladherin poses a 
unique challenge due to the commonality in structure and sequence.  
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1.3.4 HABD of CD44 
CD44 is a membrane-associated glycoprotein of the family of hyaladherin with a Type B 
Link module. The protein consists of three domains: an extracellular hyaluronan binding domain 
(HABD), a transmembrane domain, and an intracellular domain. 14 isoforms of CD44 exist that 
vary in the transmembrane domain. The intracellular domain or cytoplasmic domain is involved 
with signaling cascades including the PI3K and MAPK pathways.84 The 14 different isoforms of 
CD44 include a consensus functional HABD of approximately 150 residues that are conserved.84 
The structure of the HABD and the interaction it makes with oligosaccharides of HA has been 
studied using structural biology. The murine CD44 (mCD44) and human CD44 (hCD44) HABD, 
recombinantly expressed from Escherichia coli, have been crystallized.85,86 Structural efforts have 
employed the murine isoform (86% sequence identity with the human protein) of the CD44 HABD 
domain as the crystal packing allows for soaking of small molecules into binding sites of the protein 
(Figure 1.1). A structure of mCD44 with an oligosaccharide of HA (PDBid: 2JCR), shows that the 
HABD contains an extended binding groove (800 Å2) joined by β2-α1, α2-β3, and β4-β5 loops that 
can accommodate binding of HA.85 Ten residues of the Link module (Arg45, Tyr46, Cys81, Arg82, 
Tyr83, Ile100, Ala102, Ala103, His105 and Tyr109) make hydrogen bonding interactions with the 
oligosaccharide (Figure 1.2). The HABD has no well-formed or deep pockets that would serve as 
attractive binding sites for small-molecule inhibitors and is known to undergo small but important 
conformational changes upon binding HA.85 The protein-polysaccharide complex resembles 
protein-protein interactions that are difficult to effectively disrupt with small-molecules.87 Previous 
biophysical studies have quantified the KD of HA-8 (an oligosaccharide in length of 8 saccharide 
units) using isothermal titration calorimetry (ITC) to be 125 µM and using surface plasmon 
resonance (SPR) to be 16.7 µM.85,88 CD44 responds differently to HA dependent on the length of 
HA: polymeric-HA promotes structural integrity89,90 while HA fragments (<500 kDa) trigger 
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signaling cascades resulting in stimulation of the innate immune response91, recruitment of immune 
cells90 and tumor growth74,75,92,93. 
 
 
Figure 1.1 Comparison of hCD44 and mCD44 
Overlay of hCD44 (PDBid: 4PZ4) in magenta and mCD44 (PDBid: 5BZC) in blue. Amino acid 




Figure 1.2 Interaction of HA within Hyaluronan Binding Groove (PDBid: 2JCR) 
1.3.5 Antagonism of CD44-HA Interactions 
Selective antagonism of CD44-HA interaction could be a useful treatment to slow 
progression and metastasis in certain types of cancer.63 Several different approaches have been 
taken to interrupt HA-CD44 interactions. Monoclonal antibodies that block CD44 binding to HA 
were found to reduce tissue swelling and inflammation by inhibiting immune cell infiltration.94,95 
In clinical trials, anti-CD44 antibodies, against overexpressed CD44 variants, conjugated with a 
cytotoxic molecule can selectively deliver the drug to cells expressing the specific variants and thus 
can inhibit CD44 interactions/signaling and can cause apoptosis.96–100 Unfortunately, these 
conjugated antibodies caused toxicity leading to phase I clinical trials being halted. Other than 
antibodies, some small-molecules have been used to antagonize the CD44-HA interaction. Short 
HA-oligosaccharides (6-18 saccharide units) were able to inhibit downstream cell survival and 
proliferation pathways through competitive inhibition of CD44 interactions with full-length 
HA.92,101–103 Work in the Finzel laboratory has led to the discovery of an inducible small-molecule 












(THIQ) pharmacophore.88 These THIQ molecules were able to antagonize CD44-HA interactions 
with low millimolar IC50 values.88 Information on the structure-based design of the THIQ-series of 
molecules is discussed in greater extent in Chapter 4. Recently, verbascoside was found to inhibit 
CD44-dimerization and computational studies postulated that the natural product was able to 
interact with the HA-binding groove of CD44 (discussed in more detail in Chapter 5).104 
1.4 Malate Dehydrogenase I (MDH1) 
1.4.1 The Warburg Effect 
Normal differentiated cells metabolize glucose to carbon dioxide by oxidation of glycolytic 
pyruvate in the mitochondrial tricarboxylic acid (TCA) cycle. This series of reactions produces 
NADH from NAD which can then be used to drive oxidative phosphorylation to maximize 
production of adenosine triphosphate (ATP), the “energy currency” of the cell. ATP is considered 
“energy currency” as the hydrolysis of ATP to adenosine diphosphate (ADP) yields Gibbs-free 
energy of -7.3 kcal/mol which provides the energy for many essential processes including 
intracellular signaling, DNA and RNA synthesis, purinergic signaling, active transport, and muscle 
contraction. In the absence of oxygen, cells undergo anaerobic respiration where pyruvate is 
reduced to lactate yielding the oxidation of one NADH molecule to NAD+ for a less efficient 
generation of ATP (2 moles of ATP/mole of glucose in anaerobic respiration compared to ~36 
moles of ATP/mole glucose in oxidative phosphorylation). In 1924, Otto Warburg discovered that 
unlike normal tissues, cancer cells metabolize glucose into lactate even in the presence of sufficient 
oxygen concentrations to support oxidative phosphorylation. The process is now referred to as the 
Warburg effect or aerobic glycolysis. Converting glucose into lactate instead of into pyruvate 
subverts the TCA (cycle) and allows for more efficient synthesis of biomass through anabolism 
necessary for rapid cellular growth and cellular division, hallmarks of cancer progression. 
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1.4.2 NAD(P)H-Dependent Oxidoreductases 
The NAD(P)H-dependent dehydrogenases are a family of enzymes that use either 
nicotinamide adenine dinucleotide (NAD) or nicotinamide adenine dinucleotide phosphate 
(NADP) as cofactors in enzymatic activity and are found in many of the steps involved in oxidative 
phosphorylation, anerobic glycolysis, and aerobic glycolysis.105 The NAD(P)H-dependent 
oxidoreductases are able to oxidize their substrates by transferring a hydride group to NAD+ and 
many oxidoreductases are able to complete the reaction in the opposite direction (transferring a 
hydride group from NADH) to reduce the substrate.105 The nicotinamide ring of NADH/NAD+ is 
directly involved in the transfer of electrons during NADH oxidation.106 The C4 position of the 
nicotinamide ring is able to act as the acceptor/donor of the proton during enzymatic activity.106 
The presence of the phosphate group on NADPH modifies the structures of the cofactor and allows 
for difference in enzyme specificity for a given cofactor.105 Typically NADH/NAD+ are used in 
catabolic pathways while NADPH/NADP+ enzymes are used for anabolism.107,108 NADH/NAD+ 
ratio depends upon the availability and redox state of external electron acceptors while 
NADPH/NADP+ pool is maintained in a more reduced state to efficiently provide power for 
biosynthesis.109,110 
Many NAD(P)H-dependent oxidoreductases exist, but the majority contain a common 
structural motif that is the nucleotide binding domain of the enzyme. The most common fold of this 
structural motif is the Rossmann fold but a variety of less common motifs exists that can also bind 
the cofactor.111 The Rossmann fold, named after Michael Rossmann who discovered the fold in 
lactate dehydrogenase, is a conserved motif present in other NAD(P)H-binding enzymes.112,113 The 
Rossmann fold consists of two parallel b-strands separated by an a-helix with a tight loop between 
the first b-strand and a-helix which establishes direct contact with the cofactor (Figure 1.3).113 The 
loop contains a consensus sequence of G-X-G-X-X-G/A (X is any amino acid).114,115 The glycine-
rich loop hydrogen bonds with the phosphate portion of the NAD(P)H/NAD(P). Computational 
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analysis revealed an invariably water molecule position that bridges the phosphate to the glycine-
rich loop.116 The oxidoreductases typically contain two instances of the Rossmann fold: one 
interacts with the adenine moiety and the other with the nicotinamide ring. The Rossmann fold can 
be extended with additional b-strands, usually parallel strands but antiparallel strands are also 
observed, to form a larger b-sheet.117 The catalytic domain, which coordinates the substrate and 
provides the residues for the redox reaction to occur, is more variable amongst the NAD(P)H-
oxidoreductases.105  
Malate dehydrogenase (MDH) is an NAD-dependent oxidoreductase that reversibly 
catalyzes the reaction of malate to oxaloacetic acid using NADH as a cofactor.118 Humans express 
two forms of the enzyme: MDH1 that is localized in the cytosol and MDH2 that is localized in the 
mitochondria and is involved in the TCA cycle.118 MDH1 participates in the malate/aspartate 
shuttle that shuttles reducing equivalents instead of NAD/NADH across the mitochondrial 
membrane.118 Kinetics have shown that the enzymatic activity is an ordered reaction with 






Figure 1.3 Rossmann Fold Structural Motif 
a. Diagram of the secondary structure topology of the core Rossmann fold. b. NADH contacts 
the tight loop formed between b-strand 1 and the a-helix. Figure 1.3 was used with permission 
from: Vidal, L. S.; Kelly, C. L.; Mordaka, P. M. Heap, J. T. Review of NAD(P)H-dependent 
oxidoreductase: Properties, engineering and application. Biochimica et Biophysica Acta – 
Proteins and Proteomics 2018, 1866 (2) 327-347. 
1.4.3 Malate Dehydrogenase I (MDH1) Works with LDHA in The 
Regeneration of Cytosolic NADH 
Cancer cells are known to exhibit increased glucose consumption while uncoupling 
glycolysis from the TCA cycle and shunting carbons from glucose into the biosynthesis of 
macromolecules to support the rapid growth and proliferation characteristic of cancer 
progression.120 To meet the need of increased rate of glycolysis, a constant supply of NAD is 
required.120 The cytosolic NAD serves as an electron acceptor for glyceraldehyde-3-phosphate 
dehydrogenase (GADPH) which catalyzes the conversion of glyceraldehyde-3-phosphate to 
glycerate-1,3-biphosphate, the sixth step in glycolysis.120,121 The cytosolic NAD/NADH pool is 
separate from the mitochondrial pool of NAD/NADH that is involved in the electron transport 
chain.120 The regeneration of cytosolic NAD from NADH has been attributed to lactate 
dehydrogenase (LDH) that converts pyruvate to lactate.120,122 The shunting of glucose carbons into 
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biomass means that less carbon atoms can make it through glycolysis meaning lower concentrations 
of pyruvate and therefore other enzymatic interactions are required to maintain cytosolic NAD 
levels.123,124 Recent efforts by the Kelekar laboratory in the Department of Laboratory Medicine 
and Pathology at the University of Minnesota has led to the discovery that hMDH1 complements 
LDH in replenishing cytosolic NAD levels for enhanced glycolysis during cancer progression.125 
Using a previously established isogenic model, deuterium flow was traced from glucose 
isotopomer, [4-2H]-glucose, to cytosolic NADH and metabolites from NADH-dependent 
dehydrogenase activity.124,125 The largest concentrations of deuterium were traced to lactate, 
aspartate, and fumarate where the latter two originate from malate.125 The assay points to the fact 
that MDH can support LDH in supplying the cytosolic level of NAD. Jurkat cells knocked-out for 
MDH1 proliferate at a slower rate and consume less glucose than their wild-type counterparts.125,126 
Use of The Cancer Genome Atlas (TCGA) database and cBioPortal, showed that MDH1 is 
amplified in almost 11% of one squamous cell lung carcinoma dataset.127,128 
1.4.4 Structural Comparison of the Malate Dehydrogenases from a 
Variety of Species  
While the human cytosolic human malate dehydrogenase I (hMDH1) has not been 
structurally characterized, several other structures of homologous proteins have been solved and 
deposited into the Protein Data Bank (PDB).129 Structural data has been described for the 
mitochondrial isoform from E. coli (PDBid: 5KKA130; 3HHP131; 2CMD132), plants (PDBid: 
1SMK133), and mammals (sus scrofa, PDBid: 1MLD134) and cytosolic isoform from several species 
including bacteria (PDBid: 1BMD135; 4TVO136), plants (5NUE137), and mammals (sus scrofa, 
PDBid: 5MDH138). The human isoforms of malate dehydrogenase share only 26% sequence 
identity but share common structural features. The MDHs are stable as dimers with each monomer 
containing two structurally and functionally distinct domains.118,132 Located near the N-terminus, 
the NAD-binding domain contains the Rossmann fold motif with two additional b-strands to form 
a parallel b-sheet.132,139 The substrate binding site and amino acids that are necessary for catalysis 
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are located in the other C-terminal domain.132 The active site is the cleft formed by these two 
domains.132 Molecular binding of the cofactor is stabilized through a series of hydrogen bonds with 
the amino acids in the active site (Gly13, Gln14, Ile15, Ser88, Asn130, His186, and Ser240; 
Residue numbers for ssMDH1 (PDBid: 5MDH)), (Figure 1.4). The dimer interface consists of 
mainly interacting a-helices.140 Formation of the enzyme-cofactor-substrate ternary complex 
causes a protein conformational change in which a loop closes over the active site to screen the 
substrate and catalytic residues from the solvent.141,142 The active site contains a histidine/aspartate 
pair that provides proton transfer and binding of the substrate carboxylate is anchored by the 
guanidinium portion of an arginine.143 MDHs have been shown to distinguish between their 
substrates and other structurally similar hydroxy-acid substrates in the TCA cycle: MDH is six 
orders of magnitude less efficient using pyruvate and lactate than its natural substrate which can be 
attributed to the mobile loop switch.138 This highlights the molecular recognition of the MDHs 
which could be exploited to selectively inhibit MDH over other oxidoreductases.  
hMDH1 as a target for the development of cancer therapeutics (potentially co-administered 
with an LDH inhibitor) has been potentiated by the work done by Dr. Ameeta Kelekar’s 
laboratory.125 To enable structure-guided drug design of hMDH1, structural data is required. 
Structural data of the human isoform will allow for the understanding of the binding modality of 
the substrates and cofactor and enable the design of molecules which can perturb the enzymatic 
activity as cancer therapeutics. Comparison of the structures of the mitochondrial and cytosolic 




Figure 1.4 Hydrogen Bonding Network of NADH in MDH1 
Figure 1.4 was used with permission from: McCue, W.; Finzel, B. C. Structural characterization 
of the human cytosolic malate dehydrogenase I. ACS Omega. Manuscript Submitted. 
1.5 Caspase-3 
1.5.1 Tauopathies  
Tauopathies is a broad term that refers to diseases that are plagued by irregular deposition 
of microtubule-associated-protein tau (commonly referred to as tau).144–146 Tau levels are elevated 
in a variety of disease states including Alzheimer’s disease, progressive supranuclear palsy, 
corticobasal syndrome, frontotemporal dementias, and chronic traumatic encephalopathy, to name 
a few.147 Alzheimer’s disease (AD) is the most common tauopathy, and according to the 
Alzheimer’s Association more than 6 million Americans are living with AD (1 in 9 people age 65 
or older).148 Total payments for all individuals with Alzheimer’s is estimated at $355 billion and is 
expected to rise to $1.1 trillion in the year 2050.148 Short term memory loss (forgetting 
conversations or recent events) is the first sign of AD.147 As the disease progresses, severe memory 









are some medications that can slow the progression of AD symptoms, but there is currently no 
available therapeutic that can cure AD.147 
1.5.2 Caspase Family of Proteins 
Apoptosis or programmed cell death plays a role in the development and homeostasis of 
all multicellular organisms.149,150 The term ‘apoptosis’ is credited to John Kerr, Andrew Wyllie, 
and Alastair Currie in 1972 where they used it to describe a mode of death associated with 
fragmentation of genomic DNA.151 Along with fragmentation of genomic DNA, apoptosis is 
characterized by cytoplasmic and chromatin condensation, nuclear pyknosis, cell rounding, 
membrane blebbing, cytoskeletal collapse and the formation of membrane-bound apoptotic 
bodies.152 Studies involving Caenorhabditis elegans (C. elegans) found that 131 out of 1090 
somatic cells undergo programmed cell death during normal development leading to the discovery 
of cell lineage-dependent programmed cell death.153,154 The central components of the programmed 
cell death machinery in C. elegans are three cell death abnormal proteins (commonly referred to as 
CED). In 1993, the cysteine protease encoded by the ced-3 gene was found to be structurally similar 
to the human interleukin-1b-converting enzyme (later renamed Caspase-1).155–157 Overexpression 
of Caspase-1 was found to be sufficient to induce apoptosis in mammalian cells.158 To date, 11 
human caspases (Caspase-1 through Caspase-10, and Caspase-14) have been discovered and 
classified.  
Caspases are of the family of endoprotease enzymes that are involved in maintaining 
homeostasis, regulating cell death and inflammation, and developing normal organ functions.159 
Caspases nucleophilically cleave enzymes at cysteine and aspartate residues which is where they 
get their name Caspases (Cysteine aspartic proteases) and were first discovered by Nobel Laureate 
Robert Horvitz.157 The Caspase family of proteins share a number of characteristics that separate 
them from other proteases. Caspases are synthesized as inactive zymogens that are activated by 
proteolytic cleavage to remove the prodomain and separate the p20 large subunit and p10 small 
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unit (Figure 1.5).160 Activation of the caspases can follow an intrinsic or extrinsic pathway based 
on the origin of the signal.161 The catalytic dyad is present on the p20 subunit and consists of an 
active site Cys285, which is a part of the conserved Q-A-C-X-G pentapeptide sequence, and His237 
(numbering for Caspase-1).162 Caspases recognize at least four contiguous amino acids and cleave 
after the C-terminal residue, usually an aspartic acid residue. The pentapeptide that covalently binds 
to the catalytic cysteine during cleavage is referred to as P1 and the amino acids extending from 
the N-terminus are called P2, P3, etc. Caspases can be classified by two methods. First, Caspases 
can be classified on the basis of their known major functions: pro-apoptotic (Caspase-2, -3, -6, -7, 
-8, -9, 10) and pro-inflammatory (Caspase-1, -4, -5).160 The pro-apoptotic Caspases, as the name 
implies, are mainly involved in mediating cell death signaling transduction, while the pro-
inflammatory Caspases regulate cytokine maturation during inflammation.160 Second, the Caspases 
can be classified by the length of their prodomains which corresponds to their positioning within 
the apoptotic signaling pathway: initiator Caspases (Caspase-1, -2, -4, -5, -8, -9, -10) and 
executioner Caspases (Caspase-3, -6, -7).160 The initiator Caspases contain a long prodomain that 
contains either the death effector domain (DED) or the caspases recruitment domain (CARD).160 
This subgroup of Caspases are involved with interacting with the upstream signaling molecules 
within the apoptosis cascade. Executioner Caspases, on the other hand, contain a short prodomain 
and are typically processed and activated by upstream initiator Caspases before performing 





Figure 1.5 Caspase Activation 
(A) Structure of a procaspase-7 zymogen (PDB code 1K86). Compared to that of the inhibitor-bound caspase-7, the conformation of the active 
site loops does not support substrate binding or catalysis. The L2′ loop, locked in a closed conformation by covalent linkage, is occluded from 
adopting its productive and open conformation. (B) Structure of an active and free caspase-7 (PDB code 1K88). The active site loops are still 
flexible. Despite an interdomain cleavage, the L2′ loop still exists in the closed conformation, indicating an induced-fit mechanism for binding 
to inhibitors/substrates. (C) Comparison of the conformation of the active site loops. Compared to the procaspase-7 zymogen or the free caspase-
7, the L2′ loop is flipped 180o in the inhibitor-bound caspase-7 to stabilize loops L2 and L4. Figure 1.5 was used with permission from: Shi, Y. 
Mechanisms of Caspase Activation and Inhibition during Apoptosis. Molecular Cell 2002, 9 (3), 459-470. License Number: 512159030700 
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1.5.3 Role of Cas-2 in Neurodegenerative Diseases 
Microtubule-associated-protein (MAP) tau (commonly referred to as tau or tau protein) 
functions primarily in stabilizing microtubules (MT) especially in the axons of neurons.163 There 
are six major isoforms that arise from alternative splicing from a single encoding gene.163 The C-
terminal portion contains a MT-binding domain that is composed of multiple instances of a highly 
conserved tubulin-binding domain.164 The rest of the protein is characterized by a basic proline-
rich region and a highly acidic N-terminus region referred to as the ‘projection domain’.164 Studies 
have substantiated a model where the tubulin-binding domains bind to specific pockets on b-tubulin 
at the inner surface of the MTs, the positively charged proline-rich regions are bound to the 
negatively charged MT surface, and the highly acidic residues near the N-terminus protrude from 
the MT surface due to charge-charge repulsion.165,166 b-tubulin pockets of adjacent protofilaments 
can be occupied by different repeats of the same MT-binding domain of tau thus crosslinking 
multiple MTs to further contribute to MT stabilization.165 Binding affinity of tau for MTs is 
regulated by serine/threonine-directed phosphorylation.167 Kinase-mediated phosphorylation 
detaches tau from MT while dephosphorylation reaction by phosphatases restores MT-binding 
ability of tau.167 Phosphorylation of tau leads to the increase of cytosolic unbound tau where it 
becomes more susceptible to undergo misfolding and thus more prone to aggregation referred to as 
pretangles.168–170 Pretangles can transition to form paired helical filaments (PHFs) and then self-
assemble to form neurofibrillary tangles (NFTs).171 
Neurodegenerative disorders, where tau no longer binds to the MTs and instead it becomes 
sequestered into NFTs in neurons, are collectively referred to as tauopathies.172,173 The largest 
burden of tau pathology results from hyperphosphorylated tau leading to aggregation of tau 
filaments to form glial and neuronal tangles in dystrophic neurites.174 Disturbances in the normal 
structural and regulatory functions in the cytoskeleton compromise axonal transport and thus 
contribute to synaptic dysfunction and neurodegeneration.175,176 Aberrantly phosphorylated forms 
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of tau aggregate into insoluble fibrils that accumulate in the soma and dendrites of neurons where 
they have been associated with perturbed kinesin protein function and axonal transport and 
cytotoxicity.177,178 In the brain, the assembly of these insoluble fibrils occurs rapidly and once they 
form they persist indefinitely.179 In humans with AD, the percentage of neurofibrillary tangles 
increase with the progression of symptoms.180 The electrophysiological properties of the neurons 
of mice are unaffected by the presence of neurofibrillary tangles.181–183 Global neural network 
dysfunction occurs in mice with modest numbers of neurofibrillary tangles, and both memory 
deficits and neuron death can be dissociated from these fibrillar inclusions.181–183 The lack and 
functionality of neurofibrillary tangles in these mouse models, led researchers in Dr. Karen Ashe’s 
laboratory at the University of Minnesota to the discovery that neural network disruption can be 
caused by soluble forms of tau disrupting synaptic function.184 Using a comparison of memory-
impaired and unimpaired rTg4510 mice, a 35-kDa tau cleavage product was upregulated in 
impaired mice relative to unimpaired mice.183–185 Completing a tryptic digest of the excised 35-kDa 
product found a peptide that corresponds to residues 299-314 suggesting that the fragmented tau 
product is generated by proteolysis at Asp314 and therefore was considered Δtau314.184 Using a 
MEROPS protease database, it was found that only Caspases are able to cleave tau at Asp314.184,186 
Screening of all of the Caspases with tau, found that Caspase-2 is the only Caspase able to generate 
Δtau314 which leads to synaptic dysfunction and impaired cognition and is elevated 3-fold in AD 
brain.184 rTg4510 mice dosed with anti-Caspase-2 morpholino oligonucleotides for 28 days 
exhibited 67% lower Δtau314 levels than mice dosed with vehicle-control, highlighting that 
Caspase-2 activity can be inhibited through use of targeted molecules.184 Targeting Caspase-2 with 
a selective inhibitor should preserve cognitive function in tauopathies.  
1.5.4 Caspase Structure and Comparison of Cas-2 and Cas-3 
Structural biology efforts on several Caspases has led to valuable insight into the basis of 
caspase specificity and catalytic mechanism.187 Crystal structures of many of the Caspases have 
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been solved: Caspase-1188, Caspase-2189, Caspase-3190, Caspase-4 (PDBid: 6NRY, manuscript to be 
published), Caspase-6191, Caspase-7192, Caspase-8193 and Caspase-9194. Active Caspases are 
comprised of a homodimer with the monomeric unit containing a large and small subunit.160 Six 
anti-parallel b-strands of each monomer from a continuous 12-stranded b-sheet in the active 
enzyme that are surrounded by several a-helices and short b-strands which gives rise to the globular 
fold.160 Each monomer has an active site which is formed by four protruding loops termed L1-L4 
located at two opposite ends of the b-sheet (Figure 1.6).160 L1 originates from the large subunit 
whereas the L3 and L4 loops come from the small subunit.160 The L2 loop, which contains the 
catalytic cysteine, is cleaved between the large and small subunits into two segments.160 L1 and L3 
are relatively conserved in length and composition amongst the Caspases while L2 and L4 exhibit 
greater variability.160 Selectively targeting Caspase-2 will require an in-depth understanding of L4 




Figure 1.6 The Caspase Fold 
Caspase-2 and Caspase-3 exhibit similar quaternary structure but vary in their substrate 
binding pocket which could be used for the basis of designing a selective molecule as described by 
Maillard et. al.195 Important differences in the shape and size of the S2 subsite of Cas-2 and Cas-3 
can be observed (Figure 1.7). Tyr204 in Cas-3 is replaced with Ala228 in Cas-2 and the Phe279 in 
Cas-2 moves approximately 3 Å towards the substrate binding site relative to the Cas-3 Phe256. 
The Cas-3 S2 subsite is lipophilic and forms a round, bowl-like shape that can preferentially bind 
shorter hydrophobic resides.196 The S2 subsite of Cas-2 on the other hand forms a long groove that 
runs perpendicular to the active site cleft. Targeting this groove with either longer R-groups or 
bulkier amino acids (that would likely sterically clash with Tyr204 in Cas-3) could be an effective 
strategy in selectively targeting Cas-2. Another key difference between the two Caspases is the 
presence of an acidic amino acid, Glu52, that can engage P3 R-groups. The final difference is that 
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P5 substituents within the S5 subsite are tolerated and beneficial. Caspase-3 can be used in 
homology modeling of Cas-2 bearing in mind the structural differences described above for the 
successful generation of a potent and selective Cas-2 inhibitor. Once procedures and methodologies 
for Cas-2 yield co-crystal structures, Cas-2 and Cas-3, co-crystallized with the same molecules, can 
be directly compared for differences in binding modality and interactions with the active site.  
 
Figure 1.7 Comparison of the S2 Subsite in Cas-2 and Cas-3 
Figure 1.7 was used with permission from: Maillard, M. C.; Brookfield, F. A.; Courtney, S. M.; 
Eustache, F. M.; Gemkow, M. J.; Handel, R. K.; Johnson, P. D.; Kerry, M. A.; Krieger, F.; 
Meniconi, M.; Sanjuan-Munoz, I.; Palfrey, J. J.; Park, H.; Schaertl, S.; Taylor, M. G.; Weddell, 
D; Dominguez, C. Exploiting differences in caspase-2 and -3 S2 subsites for selectivity: 
Structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based 








2. Structural characterization of the human cytosolic 
malate dehydrogenase I 
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The first crystal structure of the human cytosolic malate dehydrogenase I (MDH1) is 
described. Structure determination at high resolution (1.65 Å)	followed	production, isolation and 
purification of human MDH1 using a bacterial expression system. The structure is a binary complex 
of MDH1 with only a bound malonate molecule in the substrate binding site. Comparisons of this 
structure with malate dehydrogenase enzymes from other species confirm that the human enzyme 
adopts similar secondary, tertiary, and quaternary structure, and that the enzyme retains much the 
same conformation even when nicotinamide adenine dinucleotide (NAD) is not bound. A 
comparison to the highly homologous porcine (sus scrofa) MDH1 ternary structures leads to the 
conclusion that only small conformational differences are needed to accommodate binding by 
NADH or other NAD mimetics, but that even NAD binding elements are somewhat flexible.  
Comparison of hMDH1 to the human mitochondrial malate dehydrogenase (hMDH2) reveals some 
key differences in the a7-a8 loop, which lies directly beneath the substrate binding pocket. These 
differences might be exploited in the structure-assisted design of selective small molecule inhibitors 




Malate dehydrogenases belong to the family of nucleotide-binding proteins referred to as 
NAD-dependent dehydrogenases or oxidoreductases.105 This enzyme family includes the lactate 
dehydrogenases (LDHs), the liver alcohol dehydrogenases (LADHs), and the glyceraldehyde-3-
phosphate dehydrogenases (GADPHs), among others.105  Malate dehydrogenase reversibly 
converts malate to oxaloacetate with the use of NAD+/NADH as a cofactor in the tricarboxylic acid 
cycle.118 Eukaryotic cells contain two main isoforms which differ in their cellular 
compartmentalization and role in cellular processes: malate dehydrogenase II (MDH2) is found in 
the mitochondrial matrix where it is involved in the citric acid cycle, while malate dehydrogenase 
I (MDH1) is localized in the cytosol where it is important to the malate/aspartate shuttle of the Urea 
Cycle.118 
Malate dehydrogenase I is overexpressed in a variety of cancers, and MDH1 amplification 
in human tumors is a common aberration that correlates with poor prognosis.197 A hallmark of 
cancer cells is increased glucose consumption required for production of macromolecules necessary 
for growth and division.120 Cytosolic NAD levels are independent of mitochondrial NAD levels 
involved in the electron transport chain.122 Increased cytosolic concentrations of NAD are 
necessary to maintain the enhanced glycolysis of proliferating cancer cells, which has largely been 
attributed to the production of lactate through LDH activity.120,122 Recently, it has been shown 
through the use of glucose isotopomer tracing in N5 cells that MDH1 supports LDH in the 
replenishing of cytosolic NAD.125 The same study also showed that Jurkat cells with MDH1 
knocked out (MDH1 KO.1 and MDH1 KO.2) show slower proliferation and glucose consumption 
than cells with functional MDH1.125 This observation leads to the possibility that an MDH1 
selective inhibitor, used either alone or in combination with LDH inhibitors, might slow tumor 
growth and cancer progression in patients.     
Structural studies employing crystallography have been used to study malate 
dehydrogenase enzymes.  Structures are known for mitochondrial (MDH2) enzymes from E. coli 
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(5KKA 130; 3HHP 131; 2CMD 132), plants (1SMK 133), and mammals (sus scrofa, 1MLD 134).  These 
MDH2 enzymes all share high sequence homology to human MDH2 (55-95%), but are distinct 
from the cytosolic (MDH1) enzymes that share lower homology (25-30%).  Human MDH1 and 
MDH2 share only 26% sequence identity.  Cytosolic MDH1 enzymes structures have been 
investigated from several species including bacteria (1BMD 135; 4TVO 136), plants (5NUE 137). 
These enzymes share good sequence homology with the human MDH1 (50-62% identity).  
Collectively, this work has confirmed that the structures are quite homologous across all species. 
All MDH enzymes share a common Rossmann fold motif characteristic of other NAD(P) binding 
dehydrogenases 139, highly similar NAD+/NADH binding sites and mechanisms of catalysis. 
Banaszak’s group at the University of Minnesota completed some of the first high 
resolution crystallographic studies with porcine (sus scrofa) MDH1 that shares very high (95%) 
sequence identity with the human enzyme over 25 years ago 138,198, but to date no human MDH1 
structure has been reported. Given renewed interest in hMDH1 as a possible therapeutic target, we 
have sought to obtain a crystal structure of the human enzyme in order to enable direct structure-
aided design of an hMDH1 inhibitor. Here we report the first structure of the cytosolic human 
malate dehydrogenase I and compare it to both previously determined structures of other 
homologous cytosolic MDHs, and also to the structures of the human mitochondrial MDH 
(hMDH2).  The monoclinic crystal form with malonate but no NAD+/NADH bound provides a 
unique view of this emerging target for pharmaceutical development. 
2.3 Materials and methods 
2.3.1 Reagents 
Full-length hMDH1 was a gift of Dr. Ameeta Kelekar (University of Minnesota, 
Department of Immunology, Minneapolis, MN). pGS-21a containing full-length mdh1 was 
purchased from GenScript. All enzymes used for DNA digestion were purchased from NEB 
(Ipswich, MA). All DNA purification kits were purchased from Qiagen (Venlo, Netherlands). 
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Components necessary for protein production other than IPTG were ordered from VWR (Randor, 
PA). HisTrap HP column for protein purification was purchased from formerly GE Life Sciences, 
now Cytiva (Marlborough, MA). All other materials necessary for protein purification and 
isolation, crystallization, and determination of enzymatic activity were purchased from Fischer 
Scientific (Waltham, MA).  
2.3.2 hMDH1-pMCSG7 construct and expression 
Mini-prepped pcDNA 3.1-mdh1 was digested with Xho1 and BamHI at 37C for 30min, the 
enzymes were heat inactivated at 80C for 3min. pMCSG7 was also digested using Xho1 and BamHI 
at 37C for 30min, the enzymes were heat inactivated at 80C for 3min. pMCSG7 was also treated 
with antartic phosphates at 37C for 30 min followed by a heat inactivation at 65C for 20min. The 
mdh1 gene (roughly 1000bp) and pMCSG7 (roughly 5200bp) were separated using an agarose gel, 
cut out, and purified using a gel extraction kit. The products were ligated using T4 ligase in a 3:1 
vector to insert ratio. The reaction was transformed into chemically competent DH5α cells and 
plated on LB+100µg/mL penicillin. The colonies were sequenced using the T7 and T7 term 
primers. Sequence verified plasmid was transformed into Rosetta2-pLysS (BL21 DE3) cells and 
plated on agar plates with Amp100 and Cm30. Expression parameters were varied to generate 
soluble protein. The inclusion bodies were solubilized in Urea Buffer (25 mM HEPES pH 7.2, 150 
mM NaCl, 8 M urea, and 5% glycerol) and loaded onto a 5 mL HisTrap HP column equilibrated 
with Buffer A (25 mM HEPES pH 7.2, 150 mM NaCl, 10 mM imidazole and 5% glycerol). An 
SDS-PAGE gel analysis found a band corresponding to His-tagged hMDH1 (~36 kDa) in the flow-
through fractions from the nickel column. Inability to separate hMDH1 during purification 
necessitated an exploration of solubility-tagged protein constructs to make purification easier. 
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2.3.3 Cloning, expression and purification of soluble His6-GST-
hMDH1 fusion protein 
The amino acid sequence corresponding to the full-length hMDH11-334 was codon 
optimized and cloned into a pGS-21a plasmid with additional TEV cleavage sequence using bgIII 
and XhoI restriction sites. The purchased plasmid was transformed into competent Rosetta2-pLysS 
(BL21 DE3) cells and plated on agar plates with Amp100 and Cm30. Colonies grew overnight and 
a single colony was selected and allowed to shake at 270 rpm overnight in LB media at 37°C. 1L 
LB media was inoculated with 3 mL of overnight culture and allowed to grow until OD600 reached 
0.5-0.7. Culture was cooled down for one hour at 4°C prior to being induced with 1 mM IPTG. 
Cultures were placed in 20°C incubator and allowed to shake for 16 hours. Cells were harvested by 
centrifugation at 5000g for 15 minutes and stored at -20°C overnight. Cell pellet was solubilized in 
Buffer A (25 mM HEPES pH 7.2, 150 mM NaCl, 10 mM imidazole and 5% glycerol). To this 
solution was added lysozyme (final concentration: 1 mg/mL) and 1.5 µL Benzonase prior to 
sonication for 16 minutes (30 s on, 30 s off) at 30% attenuation. Lysed cells were distributed among 
50 mL Beckman centrifuge tubes and centrifuged for 45 minutes at 45000g. Resulting supernatant 
was syringe filtered (0.45 µm) and loaded onto a 5 mL HisTrap HP column. Fusion protein was 
eluted from the column using a linear gradient of Buffer B (25 mM HEPES pH 7.2, 150 mM NaCl, 
400 mM imidazole, and 5% glycerol). Like fractions were pooled together and TEV protease was 
added to 8% w/w before adding to dialysis cassette in TEV cleavage buffer (25 mM HEPES pH 
7.2, 150 mM NaCl, 1 mM DTT, and 5% glycerol) at 4°C overnight. Contents of dialysis tubing 
was syringe filtered (0.45 µm) and loaded onto HisTrap HP column to separate hMDH1 from the 
His-tagged fusion protein. Flow through containing hMDH1 was pooled together and concentrated 
to ≤ 5 mL prior to being syringe filtered (0.22 µm) and loaded onto a Sephacryl S-100 column. 
Peaks from the size exclusion column were analyzed via SDS-PAGE and resulting hMDH1 was 
concentrated to 5 mg/mL in buffer supplemented with 10% glycerol. Aliquots were flash frozen 
before being stored in -80°C freezer for future use. Resulting yield from the preparation was 
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approximately 2.5 mg/L. Sequence was confirmed via crystallography and function confirmed via 
enzymatic activity assay.  
2.3.4 Confirming enzymatic Activity 
hMDH1enzymatic activity was assessed using a spectrophotometer to detect concentration 
of NADH at 340 nm. In short, to a vial was added NADH and oxaloacetic acid to either a vial with 
or without MDH1.199 Loss of signal at 340 nm relative to the control sample (without enzyme) 
correlates to a decrease in the NADH/NAD+ ratio as the enzyme is able to convert oxaloacetic acid 
to malate. Enzymatic activity was tested in only a qualitative manner to ensure structural integrity. 
2.3.5 Crystallization 
Protocols successfully used with Sus scrofa MDH1 served as a starting point for hMDH1 
crystallization.138  Microcrystals grew in 3-4 days by hanging drop vapor diffusion using precipitant 
consisting of 25-30% PEG 4000, 100 mM citrate buffer pH 6.5 and protein concentrated to 5 
mg/mL in buffer containing 25 mM HEPES pH 7.4, 150 mM NaCl and 10% glycerol. Previous 
researchers identified malonate (pH range 4-8) as a good buffer for crystallization of LDHA, 
another member of the oxidoreductase family200, so malonate was substituted for HEPES in crystal 
optimization. After several rounds of seeding and optimization, plate-like crystals (75 x 25 x 150 
µm) reached full maturity within 48 hours at 20°C. Final conditions yielding monoclinic crystals 
were obtained by mixing equal amounts of protein with well solution containing 28% PEG 4000, 
100 mM NaMalonate pH 7.2, and 0.15 mM ammonium acetate in 2 µL drops. Optimal cryo-
conditions involved mother liquor plus 15% PEG 400.  
2.3.6 X-ray data collection 
Diffraction data was collected at IMCA-CAT beamline 17-ID at the Advanced Photon 
Source (APS), Argonne, Illinois, USA. Collection was completed at 100 K using radiation of 
wavelength 1.00 Angstroms and a Dectris Eiger2 9M detector. Data was processed using autoProc 
and re-scaled using aP_scale using R-factor (<.4), completeness (>90%), and I/sigma (>2) as 
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criteria, and a minimum of two of the three criteria were met in determining the proper resolution 
range.201  
2.3.7 Structure solution and refinement 
Due to the high sequence similarity between Sus scrofa MDH1 and hMDH1(96%), the 
ssMDH1 model, 5MDH (chain A) was used as the search model in molecular replacement with 
Phaser.138,202 The monoclinic crystal was found to contain two protein chains in the asymmetric 
unit. Iterative rounds of refinement and model building were carried out using Phenix203 and 
Coot204. Malonate was modeled into the corresponding electron density using standard geometry 
as in the CCP4 dictionary.205 Refined structures were validated with MolProbity 206. Table 2.1 
summarizes statistics from the data collection and Phenix refinement for assessment of the quality 
of the structures.207 Atomic coordinates and reflection data for hMDH1 with malonate bound in the 
substrate binding pocket have been deposited into the Protein Data Bank.129  (Accession code: 
7RM9) A second non-isomorphous crystal form was solved using the iterative process described 
above, but no electron density corresponding to malonate was observed. (Accession code: 7RRL) 
The majority of this chapter will focus on PDBid: 7RM9 because of its superior structure quality 
and apparent relevance. Section 2.4.6 compares the two non-isomorphous crystal forms. 
2.3.8 Fragment screen using differential scanning fluorimetry (DSF) 
A fragment screen of MDH1 was completed using differential scanning fluorimetry (DSF) 
on a BioRad CFX96 Well System (Hercules, CA) and previously established protocol.208 To 
determine the optimal protein concentration, protein in varying concentration (0.3-0.01 mg/mL) 
was added to wells of a 96-well plate containing fixed concentration of Sypro-Orange (1:500 
dilution of 5000x) and SEC buffer (25 mM HEPES pH 7.2 and 150 mM NaCl) to a final volume 
of 40 µL. The parameters of the scan were 0.5°C steps from 25-80°C with a 30-second hold at each 
temperature for proper measurement of the fluorescence signal. The resulting fluorescence signals 
were curve fitted using a Boltzmann model for non-linear regression in the curve fitting software, 
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Bio-Rad CFX 2.0, present on the instrument.209,210 The optimal protein concentration was 
determined to be 0.2 mg/mL and this concentration was used for the rest of the subsequent assays. 
The cofactor, NADH, was tested in a 11-point dose-response (0.5-50 mM) DSF assay by adding 
NADH freshly dissolved in SEC buffer to the wells and using the same DSF parameters described 
above. Based off the results with NADH, 5 mM NADH was added to the well conditions for the 
DSF fragment screen. The Maybridge Ro3 Diversity Library of 1000 fragments in 96-well plate 
format were thawed at room temperature. 1 µL of 200 mM fragment was added to the 
corresponding well of the 96-well assay plate. The first and final column, were DMSO controls 
(2.5% v/v). The wells contained protein (0.2 mg/mL), Sypro-Orange (1:500 dilution of 5000x), 
NADH (5 mM), and fragment (5 mM). Same parameters were used and resulting data was fitted 
using the same Boltzmann model.  
2.4 Results and discussion 
2.4.1 Expression and purification of soluble protein 
An initial construct design included an N-terminal His-tagged protein with a TEV cleavage 
site for straightforward purification and cleavage of the tag to isolate hMDH1 for crystallographic 
and enzymatic activity studies. Over-expression of hMDH1 was qualitatively achieved with small 
volume cultures at varying temperature (16-37	°C), IPTG concentrations (0.1-1 mM) and induction 
periods (1-20 hours). Following each trial induction, 1 mL culture aliquots were collected and 
centrifuged (13000g) and SDS-PAGE gel was used to compare the amount of ~36 kDa species 
relative to an uninduced sample. Highest over-expression was observed following induction with 
1 mM IPTG overnight at 20 ºC.  
The initial construct was designed for ease of purification by nickel affinity 
chromatography, but no soluble elution was observed with a trial purification from a 1 L culture.   
A band corresponding to the molecular weight of hMDH1 was observed in the insoluble fraction. 
In an attempt to solubilize the protein, expression was done at a lower temperature (16 ºC) with use 
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of a gradient of urea during lysis (1-8 M) to solubilize the protein from the insoluble fraction. Only 
at the highest concentration of urea was the protein successfully solubilized and therefore lysis 
buffer was supplemented with 8 M urea. Again, no protein with the appropriate molecular weight 
was found in any nickel flow-through fraction. Inability to solubilize and separate the protein from 
miscellaneous proteins after cell lysis compelled us to explore alternate constructs.  
 A modified pGS-21a plasmid was engineered with a TEV cleavage site and a codon 
optimized mdh1 for bacterial expression was cloned into the modified plasmid. The rationale 
behind the engineered plasmid was to use codon optimization and a solubility-tag (GST) to increase 
likelihood of soluble protein after lysis. TEV cleavage site was included for easy cleavage of the 
solubility-tag from the isolated protein. The combination of the solubility-tag and codon 
optimization yielded soluble protein after cell lysis that was found to bind to the nickel column. 
TEV protease was able to cleave the GST-tag from hMDH1 which could then be further purified 
through a second nickel column (GST and His-tagged TEV protease stuck to the column while 
cleaved hMDH1 did not). Finally, Size Exclusion Chromatography was employed to ensure the 
highest possible	protein	purity for crystallographic and enzymatic studies. 
2.4.2 Secondary, tertiary and quaternary structure of hMDH1 
The hMDH1 crystal was found to have P21 symmetry with two protein molecules (the 
functional biological unit) in the asymmetric unit and the structure has been solved and refined to 
1.65Å resolution (Table 2.1). Each monomer adopts the Rossmann fold characteristic of other 
NAD(P) binding dehydrogenases139, comprised of nine α-helices and eleven β-strands conserved 
in all MDH structures (Figure 2.1).  A lengthy insertion in the sequence of MDH1 enzymes between 
b8 and a7 gives rise to an additional beta pair (b8a-b8b) curled into the b8-a7 loop not present in 
MDH2 enzymes.   
The site of NAD+/NADH binding in this family of structures lies at the meeting of loops 
at the edge of the large parallel beta sheet within this fold. Loops b1-a1 and b2-a2 support the 
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adenosine diphosphate, b5-a5 cradles the nicotinamide nucleoside and b4-a4 provides a sort of 
cap that lays over all.   Substrates (malate or oxaloacetate) bind just to the side of the nicotinamide 
base, pinched between alpha helices a7 and a8, held in precise position by H-bonds to universally 
conserved residues (Arg92, Arg98, Asn131 and His187).  
 Monomers assemble into biologically relevant homodimers, forming a helical bundle with 
a1 and a8 replicated across a non-crystallographic two-fold axis and winged with extensive 
contacts between a2 and a7 of opposite monomers (Figure 2.2).   While there is no direct contact 
between active sites in the two monomers, previous work has shown that MDH1 functions as a 
dimer in solution and disruption of this interaction along the dimer interface could potentially 
perturb enzymatic function.118   While the two monomers are in distinctly different crystallographic 
environments in our structure, they are quite similar overall (rmsd 0.192 Å). Crystal packing does 
influence conformational flexibility in this crystal form.  The crystallographic B-factors of a-
carbons throughout the structure are illustrated in Figure 2.3. Large B-factors are observed for 
residues 203-205 in subunit A. Amino acids in this region are modeled with lower occupancy (0.5) 
as positive difference peaks were observed in the 2Fo-Fc map but little electron density was 
observed in the Fo-Fc map. The majority of the important b4-a4 loop (residues 92-99) is disordered 
in subunit B and cannot be modeled; there is no interpretable electron density for this loop. The 
rest of the structure is well ordered, with 98% of the amino acids show favorable torsional angles 









Table 2.1 Crystal Data and Refinement Statistics for Two Isomorphous hMDH1 Crystals 
 
PDB ID code 7RM9 7RRL
Diffraction source APS 17-ID APS 17-ID
Resolution range (Å) 38.82  - 1.65 (1.709  - 1.65) 46.01  - 2.05 (2.123  - 2.05)
Space group P 1 21 1 P 1 21 1
a, b, c (Å) 51.503 84.312 77.652 67.875 62.593 74.322 
a, b, g (°) 90 91.223 90 90 91.219 90
Total reflections 144101 (15345) 76478 (7698)
Unique reflections 73789 (7932) 39102 (3914)
Multiplicity 2.0 (1.9) 2.0 (2.0)
Completeness (%) 92.56 (99.97) 99.45 (99.95)
Mean I/sigma(I) 13.90 (3.53) 8.53 (2.24)
Wilson B-factor (Å2) 17.86 30.62
Rmerge 0.02781 (0.1677) 0.04543 (0.3143)
Rmeas 0.03933 (0.2372) 0.06424 (0.4445)
CC1/2 0.999 (0.924) 0.997 (0.753)
CC* 1 (0.98) 0.999 (0.927)
Reflections used in refinement 73786 (7931) 39092 (3914)
Reflections used for R-free 3685 (392) 1979 (208)
Rwork 0.1670 (0.1846) 0.1868 (0.2508)
Rfree 0.1927 (0.2213) 0.2374 (0.2993)
CC(work) 0.967 (0.932) 0.965 (0.824)
CC(free) 0.960 (0.862) 0.946 (0.735)
Number of non-hydrogen atoms 5396 5058
  macromolecules 4994 4878
  ligands 14 0
  solvent 388 180
Protein residues 658 655
R.m.s. deviations
Bonds (Å2) 0.007 0.007
Angles (°) 0.94 0.85
Ramachandran
Favored (%) 98.62 97.53
Allowed (%) 1.38 2.47
Outliers (%) 0 0
Rotamer outliers (%) 0.92 0.97
Clashscore 2.67 3.38
Average B-factor (Å2) 19.89 29.77
  macromolecules 19.48 29.75
  ligands 20.76 N/A
  solvent 25.1 30.26
Data collection and processing




Figure 2.1 The Malate Dehydrogenase Fold and Sequence Comparison of hMDH1 and hMDH2 
A) The Malate dehydrogenase fold and secondary structure assignments. B) A structure-based alignment of human MDH1 and MDH2.  Vertical 
lines joining amino acids in the two sequences denote a 1:1 correspondence in position of residues in the structures of the two enzymes.  Boxes 
identify cofactor and ligand binding motifs. Sequence conservation marks displayed (* :, .) are from a Clustal-Omega multiple sequence alignment 
























      
huMDH1 M S E P I R V L V T G A A G Q I A Y S L L Y S I G N G S V F G K D Q P I I L V L L D I T P M M G V L D G V L M E L Q D C 60
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
huMDH2 - - - N A K V A V L G A S G G I G Q P L S L L L K N S P L V - - - - - S R L T L Y D I A - - - - H T P G V A A D L S H I 53
: * : * * : * * . . : : * : : : * * . : : .
a3 b4 a4      
huMDH1 A L P L L K D V I A T D - - K E D V A F K D L D V A I L V G S M P R R E G M E R K D L L K A N V K I F K S Q G A A L D K 118
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
huMDH2 E T - K A A V K G Y L G P E Q L P D C L K G C D V V V I P A G V P R K P G M T R D D L F N T N A T I V A T L T A A C A Q 112
: . * : : . . * : * * * * : : . * * :
      a5 b6      
huMDH1 Y A K K S V K V I V V G N P A N T N C L T A S K S A P - - - S I P K E N F S C L T R L D H N R A K A Q I A L K L G V T A 175
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
huMDH2 H C - P E A M I C V I A N P V N S T I P I T A E V F K K H G V Y N P N K I F G V T T L D I V R A N T F V A E L K G L D P 171
. : : : * * . * : . : . . : : * * * . * : : : .
      b7 b8 b8a b8a a7      
huMDH1 T A N D V K N V I I W G N H S S - T Q Y P D V N H A K V K L Q G K E V G V Y E A L K D D S W L K G E F V T T V Q Q R G A 232
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
HuMDH2 D P A R V - N V P V I G G H A G K T I I P L I S Q C T P - - - - - - - K V D - - - - F P Q D Q L T A L T G R I Q E A G T 217
: : * : . * : : : : : * :
      a8 b9      
huMDH1 A V I K A R - - K L S S A M S A A K A I C D H V R D I W F G T P E - - G E F V S M G V I S D G N S Y G V P D D L L Y S F 288
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
HuMDH2 E V V K A K A G A G S A T L S M A Y A G A R F V F S L V D A M N G K E G V V E C S F V K S - Q E - - T E C T - - Y F S T 272
: : : * : . : : * . : : : . : .
b10 b11 a9      
huMDH1 P V V I K N - K T W K F V E G L P I N D F S R E K M D L T A K E L T E E K E S A F E F L S S - 333
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
HuMDH2 P L L L G K K G I E K N L G I G K V S S F E E K M I S D A I P E L K A S I K K G E D F V K T L K 320
: . : : * . :
Residues/substructures surrounding the NAD+/NADH binding site








Figure 2.2 The Quaternary Structure of hMDH1 Viewed Along the 2-fold Axis 
Chain A shown in green and chain B in cyan. Alpha helices are labeled to give greater clarity to 
the quaternary and tertiary fold of the protein with helices from chain A labeled as a# and chain 















2.4.3 The NAD+/NADH binding site 
The structure reported here has neither NAD+/NADH or a substrate bound.  We have tried 
to form binary complexes with NADH, and ternary complexes with NADH and oxaloacetate by 
either soaking or co-crystallization under similar conditions, but these efforts have not yet been 
successful.  The ternary complex of Sus scrofa (porcine) MDH1 (PDBid 5MDH) provides a good 
basis for modeling where cofactor and substrate should be when bound together in hMDH1, and 
for identifying conformational differences in the hMDH1 crystal form that might prevent co-factor 
binding.  In the ssMDH1 complex (Figure 2.4A), hydrogen bonds from the backbone of the b1-a1 
loop anchor the adenosine ribonucleotide, sidechains of Ser89 and Asn131 engage the nicotinamide 
 
Figure 2.3 B-value Variability in hMDH1 Dimer 
The protein backbone is colored by B-factors of CA atoms with a rainbow spectrum, 









ribose, and His181 is H-bonded to the nicotinamide amide.  An overlay of key NAD+ binding 
segments (those highlighted in ) from subunit A of hMDH1 and ssMDH1 gives a rms difference in 
backbone atoms of only 0.24 Å, confirming that the hMDH1 structure is poised to accept 
NAD+/NADH with minimal conformational adaptation (Figure 2.4B).  All interactions should be 
preserved accept the H-bond to Ser88, which is flipped to a different rotamer orientation in hMDH1 
when NAD+ is absent. 
The binding elements in Subunit B are not well positioned for cofactor binding, however 
(Figure 2.4C). As mentioned above, residues 92-98 are completely disordered. While this loop 
makes little direct contact with NAD+, it forms the floor of substrate binding pocket beneath the 
nicotinamide ring, and substrates typically H-bond to the cofactor. The Gly14-Gln15 amide bond 
in Subunit B is rotated roughly 90 degrees, so that the carbonyl is directed away from the phosphate 
of NAD to which it should H-bond. Asp42-Met45, and Gly88-Pro91 have all shifted into the NAD 
binding space, effectively shrinking the binding pocket.     
We have examined crystal packing in the vicinity of NADH-binding sites in both subunits, 
but there is no simple explanation for these conformational differences; no intermolecular 
interactions exist to prevent subunit B from adopting a conformation similar to that seen in subunit 
A or vice versa.  It is interesting that structural flexibility exists, as it affirms the possibility that 





Figure 2.4 In-depth Look at tNAD Binding Interactions 
(A) ssMDH1 hydrogen bonding network with tNAD. (B) Homology model of hMDH1 hydrogen 
bonding with tNAD. (C) Comparison of the cofactor binding pocket of hMDH1 subunit A 






























2.4.4 Malonate lies in substrate binding pocket 
Electron density present in the substrate binding pocket of subunit A can be attributed to 
malonate (Figure 2.5) a component of the buffer for crystallization. No comparable density is found 
in subunit B, which, as described above, is less well-ordered. Arg92 and Arg 98, which figure 
prominently in positioning substrate molecules (see below), are completely disordered in subunit 
B. 
 
Figure 2.5 Omit Map of Malonate Bound in hMDH1 Structure. 
Map mesh vectors (blue) lying more than 1.8 Å from the ligand are hidden. 
Malonate has been modeled in the hMDH1 complex in two different conformations with 
half occupancy (Conformer A and Conformer B). The hydrogen bonding stabilizing each 
conformation is shown in Figure 2.6A. In both conformations, one carboxylate in this symmetric 
molecule is positioned opposite the plane of the Arg92 guanidinium to which it is H-bonded. In 
Conformation A, the other carboxylate interacts with Arg162, Arg98, and Ser242. In Conformation 
B, this carboxylate is rotated to hydrogen bond with His187 and the secondary amine in Arg98.  
These interactions collectively mimic those seen by more natural substrate analogs that are one 
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carbon longer and can make both sets of interactions, such as those observed in the porcine MDH1 
complex with α-ketomalonate (PDBid 5MDH) (Figure 2.6A). Interestingly, malonate binds in this 
pocket even in the absence of the NAD+ co-factor. In the α-ketomalonate complex, one oxygen of 
the carboxylate is able to hydrogen bond with an exocyclic oxygen of the nicotinamide ribose. We 
could find no other example of a malate dehydrogenase structure in the PDB that includes a bound 
substrate analog in the absence of NAD+/NADH. 
 
Figure 2.6 Comparison of Hydrogen Bonding Network Between Malonate in hMDH1 and 
α-ketomalonate in ssMDH1 
(A) Hydrogen bonding to malonate by hMDH1. (B) Hydrogen bonding to α-ketomalonate by 
ssMDH1 (PDBId: 5MDH) 
2.4.5 Differences between human cytosolic and mitochondrial MDH 
Any successful targeting hMDH1 for therapeutic purposes will require that some degree of 
selectivity be achieved over the mitochondrial MDH (hMDH2). While it has never been described 
in detail, a high resolution (1.9 Å) structure of a ternary complex of hMDH2 was solved in 2006 
by the Structural Biology Consortium and deposited in the PDB with accession code 2DFD.  Its 
















based alignment of residues with PDBeFold211 results in the pairwise alignment of sequences 
illustrated in Figure 2.1B and an RMSD of paired backbone atoms of 2.0 Å.  Despite the higher 
RMSD, hMDH2 preserves the fold and all the cofactor binding motifs with high homology.   
One feature stands out as potentially relevant to prospects for selective inhibitor design in 
the comparison of hMDH1 and hMDH2: the insertion of two extra residues into the a7-a8 loop.  
This loop passes directly under the substrate binding pocket (D-malate in the hMDH2 ternary 
complex) and contributes the surface that underpins the bound substrate (Figure 2.7). In addition 
to the insertion of two residues that results in a local shift in registry, there are specific sequence 
differences (hMDH1Ile235 to Val; hMDH1Ser242 to Ala; hMDH1A243 to Thr) that alter the shape of the 
substrate binding pocket. There are also likely significant differences in the flexibility and 
dynamics of these two loop variants in response to ligand binding.  While the malate binding pocket 





Figure 2.7 Comparison of the a7-a8 loop in hMDH1 vs. hMDH2 
hMDH2 (salmon), NAD+ and D-malate are from the ternary hMDH2 complex (PDBid: 2DFD). 
hMDH1 is shown in cyan. Overlay results upon superposition of NAD binding substructures 
identified in Figure 2.1B (RMSD 0.79Å).  The portion of this loop in contact with bound malate 
is illustrated with the fragment of surface. 
2.4.6 Comparison of non-isomorphous hMDH1 crystal forms  
Two non-isomorphous crystals forms were solved that share the same space group (P21) 
with a dimer in the asymmetric unit, but vary in the unit cell parameters, specifically the length of 
the a- and b-axes that alters intermolecular packing significantly (Table 2.1). Superimposing chains 
A of both structures shows a global RMSD difference of 0. 217 Å, but closer examination exposes 
large conformational differences between the active site loop (Figure 2.8). Gly95 moves 
approximately 10 Ångstroms between the ligand bound and empty active site conformations. This 
more open conformation is similar to one observed in E. Coli MDH2 when NAD+/NADH was not 
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present (3HHP 131). Further investigation is needed as to why one crystal yielded the closed 
(NAD+/NAPH)-bound conformation when another crystal grown under the same conditions did 
not.  
 
Figure 2.8 Examination of the difference in the a4-b4 loop that cradles NAD+/NADH in 
two crystal forms of hMDH1. 
Shown are cartoon (A) and Ca ribbons (B) of chain A in Form I (green) (PDBid: 7RM9) vs 
chain A in Form II (cyan) (PDBid: 7RRL). 
2.4.7 MDH1 unfolding exhibits biphasic transition 
A fragment screen was conducted on hMDH1 to begin the drug discovery process using 
differential scanning fluorimetry (DSF) as it is fast, robust, and inexpensive. Prior to beginning the 
actual screening campaign, conditions for the DSF assay needed to be optimized. Protein 
concentration was varied from 0.3-0.01 mg/mL with an optimal concentration of 0.2 mg/mL being 
used as it was the lowest concentration of protein that gave a robust fluorescence signal (>30,000 
RFU). An issue with the melting curves, was the presence of two denaturation transitions (~50 ºC 
and 58 ºC) made evident in the first derivative plot (Figure 2.9). Biphasic curves can originate from 
a variety of different variables: multiple protein species in solution, poorly or improperly folded 











protein, and denaturation of the quaternary structure, to name a few.212 Various conditions were 
tested to decrease the biphasic nature of MDH1 including a buffer and pH screen and the addition 
of additives, such as glycerol, to attempt to stabilize the protein fold. None of the conditions tested 
were able to decrease the biphasic nature of the curves and therefore the conditions were left 
unchanged and changes in either of the transitions would be analyzed in the fragment screen. The 
effect of NADH on the melting curve was tested in a dose-response (1-50 mM final concentration 
in the well) assay and NADH was found to cause a 6ºC positive shift in the second observed 
transition of the unfolding temperature of MDH1 relative to apo protein (64 ºC vs. 58 ºC), (Figure 
2.10). The maximal change in denaturation temperature was observed at 2.5 mM and therefore the 
fragment screen would be completed at 5 mM NADH to ensure proper saturation. Presence of 
NADH did not decrease the biphasic nature of hMDH1. Since malonate was found to bind to 
hMDH1 and mimic several of the same hydrogen bonds observed of a-ketomalonate in ssMDH1, 
it was tested in the DSF to determine the effect on protein denaturation. Malonate was found to not 












































Figure 2.10 NADH Dose-Response in DSF Assay 
 
 
Figure 2.11 Malonate Does Not Affect MDH1 Protein Stability 
2.4.8 Fragment screen produced no hits to follow-up 
A fragment screen was conducted on a Maybridge Ro3 Diversity Library of 1000 
fragments. The library is Rule of 3 compliant and therefore all fragments abide by the following 
physico-chemical properties to allow for successful lead discovery: molecular weight is <300 Da, 
number of hydrogen bond acceptors is ≤3, number of hydrogen bond donors is ≤3, and ClogP is ≤3.213 
















































Since the denaturation of hMDH1 is biphasic, compounds which caused an increase or decrease (>1ºC) 
in either of the transitions relative to DMSO were considered hit fragments in the initial screen. In drug 
discovery, traditionally, positive shifting molecules and fragments are prioritized as they increase the 
protein stability, but no chemical matter was discarded during initial screening so both positive and 
negative shifting fragments were considered hits.214 18 fragments were found to cause at least ±1ºC 
shift. To accurately confirm the fragments, initial vials from Maybridge were used. Of the 18 
fragments, 3 were unavailable for re-assay, 5 did not give a transition (fluorescence signal did not 
increase with temperature), 7 were unable to replicate the original thermal shift, and 3 caused a 
negative shift to give an initial hit rate of 0.3% which is a log-fold worse initial hit rate than 
expected for a DSF fragment screen.215 None of the original hits reproduced the Tm shift of the 
original screen and therefore there are no hits to follow-up. The fragments came from vials that 
were plated onto source plates using the Echo in the Institute for Therapeutic Drug Discovery here 
at the University of Minnesota. The source plates are thawed and refrozen each time a fragment 
screen is conducted and therefore could be susceptible to degradation. The low hit rate is indicative 
that the use of DSF to discover fragment molecules as inhibitors of hMDH1 is not the correct 
approach and other approaches such as SPR should be pursued in future work.  
2.5 Conclusions and outlook 
 The first over-expression, isolation, and purification of human MDH1 using a bacterial 
expression system has been described in detail. Further, the first hMDH1 crystal structure has been 
determined at 1.65 Å resolution with only a small molecule (malonate) bound in the active site. 
While the structure confirms that the enzyme is very similar to the previously reported porcine 
structure with which it shares 95% sequence identity, this new structure without bound NAD co-
factor provides some novel insights into the conformational flexibility of the enzyme. The b4-a4 
loop that cradles NAD+/NADH in active enzymes adopts a conformation similar to that needed 
to bind NAD+ in one crystallographic environment but is largely disordered in another. While 
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crystallization can exaggerate the importance of conformations stabilized by crystal packing, it is 
likely that this range of motion is accessible to the protein in solution as well, A more open 
conformation suggestive of extensive protein flexibility has previously been observed in an E. coli 
MDH2 apo structure, (3HHP131), but not in any MDH1 structure. This flexibility may leave the 
enzyme susceptible to inhibition by small molecule dinucleotide mimetics that trap the enzyme in 
an inactive conformation. 
The comparison of the hMDH1 structure to hMDH2 is also revealing.  Distinct differences 
in these two enzymes in the vicinity of the substrate binding pocket might be exploited in the 
discovery of small molecules that inhibit human MDH1 with selectivity over the mitochondrial 
MDH2.  This selectivity will almost certainly be a desirable attribute of any agent put forward for 
clinical evaluation of the therapeutic potential of MDH1 inhibitors in the treatment of cancer.  The 
monoclinic hMDH1 crystal form reported here may be a particularly useful tool for use in future 
crystallographic fragment screening, specifically because of its extensively open and empty active 














3. Examination of a Series of Pentapeptide Inhibitors of 





The pentapeptides were synthesized by Merlin Bresinsky and Dr. Steffen Pockes in the Institute of 
Pharmacy at the University of Regensburg. The synthesis of the molecules is not detailed, but the 
structures are included. The molecules were used in the enzymatic activity assay and for co-
crystallization with Caspase-3. Jessica Strasser in the Institute for Therapeutics Discovery and 
Development (ITDD) at the University of Minnesota completed the Caspase-3 enzymatic activity 




A background on tauopathies, the Caspase family of proteins, the role of Caspase-2 in 
neurodegenerative diseases, the general Caspase structure and a comparison of Caspase-2 and 




The grant which supported this work (5R01AG062199-03) has the broad, long-term 
objective of the development of specific caspase-2 inhibitors as neuro-therapeutic agents.216 
Caspase-3 (Cas-3) and Caspase-2 (Cas-2) are both apoptotic caspases that differ in their activation 
but share very similar protein folding (Figure 3.1) and therefore Cas-3 can serve as a surrogate 
model of Cas-2. The goal of Cas-3 crystallography is to be able to use resulting co-crystal structures 
in homology modeling and comparison of peptide binding interactions with the protein to increase 
potency and selectivity in Cas-2 inhibitor design. Crystallographic efforts in our laboratory have 
led to structure solutions of various Caspase-3 co-crystal complexes while progress on Caspase-2 
has been much slower due to inadequate protein supplies and inability to grow any crystalline 
material. The pentapeptides with Cas-3 are the only current structural depiction of the peptides (no 
small-molecule crystals or Cas-2 co-crystals), and therefore, visualization of the movement of the 
peptides and shifts in the loops of Cas-3 can guide future Cas-2 inhibitor design. This chapter of 
the thesis will solely focus on the Caspase-3 co-crystal structures and not discuss any potentiation 
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for inhibitor design for Caspase-2 based on homology modeling or future co-crystal structure 
comparison. Here we describe 10 novel pentapeptide-Cas-3 co-crystal structures and compare the 
binding modality and conformational differences observed in the L3 and L4 loops and examine 
structure activity relationships. 
 
Figure 3.1 Overlay of Cas-2 (PDBid: 3R5J, Magenta) and Cas-3 (PDBid: 2H65, Green) 
3.2 Methods 
3.2.1 Reagents 
The pET23b vector containing human Caspase-329-277 was gifted by Dr. Michelle Arkin at 
UCSF. BactoTM yeast extract and BactoTM tryptone for protein expression were purchased from 
VWR (Radnor, PA). 5 mL HisTrap HP column for nickel column chromatography and 5 mL 
HiTrap Q HP column for ion exchange chromatography used for protein purification were 
purchased from formerly GE Healthcare, now Cytiva (Chicago, IL). Isopropyl β-d-1-
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thiogalactopyranoside (IPTG) and components for protein purification including buffer 
components, syringes, and pipettes were purchased from Thermo Fisher Scientific (Waltham, MA). 
Crystal trays and cover slips for hanging drop vapor diffusion crystallography were ordered from 
Hampton Research (Aliso Viejo, CA). AFC fluorogenic substrate, Ac-DEVD-AFC, was purchased 
from Bachem (Torrance, CA). The 10 novel pentapeptides, supplied as 20 mM stock solutions in 
DMSO, were synthesized by Steffen Pockes at the University of Regensburg and has affiliation 
with the University of Minnesota. The synthesis will not be discussed in the context of this chapter. 
3.2.2 Caspase-3 Expression, Isolation and Purification 
The expression and subsequent purification were accomplished using a previously 
published protocol for caspases.217 Escherichia coli Rosetta2 pLyss DE3 cells were transformed 
with the plasmid and plated onto an LB Amp100 Cm30 agar plate. Single colony was selected and 
added to 2 mL of 2X TY media supplemented with Amp100 and Cm30 and placed in an incubator 
at 37ºC for 8 hours as the primary culture. 0.5 mL was used to inoculate 50 mL of 2X TY media 
supplemented with the same antibiotics for overnight growth. The following morning, 20 mL of 
the overnight culture was added to a fresh 1 L of 2X TY media and allowed to grow until mid-log 
phase, OD600=0.5-0.7, was achieved. Cultures were subsequently induced with 0.2 mM isopropyl-
b-D-thiogalactosidase (IPTG) and incubated at 30ºC for 5 hours with 270 rpm shaking. Cell pellet 
was recovered through centrifugation at 4000g for 10 minutes to which 30 mL of resuspension 
buffer (100 mM Tris pH 8.0, 100 mM NaCl) prior to storage at -20ºC overnight. The cell pellet 
solution was removed from the freezer and thawed at 37ºC prior to sonication for 8 minutes (30 
seconds on followed by 30 seconds off) in an ice bath. The lysed cells were spun down at 20000g 
for 30 minutes and the resulting supernatant was syringe filtered (0.45 µM) prior to loading onto a 
HisTrap nickel column pre-equilibrated with the resuspension buffer. Bound lysate was washed 
with a washing buffer (100 mM Tris pH 8.0, 500 mM NaCl) and eluted from the column using a 
linear gradient of elution buffer (100 mM Tris pH 8.0, 100 mM NaCl, 400 mM imidazole). SDS-
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PAGE gel analysis was performed on fractions from the column, and like fractions corresponding 
to Cas-3 were pooled together and diluted 1:3 (protein:buffer) with a 100 mM Tris pH 8.0 buffer 
without salt. The diluted protein was loaded onto an ion-exchange column and eluted from the 
column with buffer containing 100 mM Tris pH 8.0 with ~175 mM NaCl. Presence and purity of 
Caspase-3 was analyzed using SDS-PAGE and an enzymatic activity assay. Like fractions were 
pooled together and diluted to 0.5 mg/mL with added 10% glycerol prior to flash freezing in liquid 
nitrogen and storage at -80°C. Typical yield for the expression, isolation, and purification was 
approximately 3 mg/L. 
3.2.3 Caspase-3 Enzymatic Activity Assay 
The enzymatic assay was performed in a 96-well plate format and Caspase-3 inhibition by 
compounds were measured in fluorometric assays.  Caspase-3 was expressed, isolated, and purified 
as described above. Enzyme was diluted to 2.07 nM/well in buffer containing 100 mM HEPES pH 
7.0, 150 mM NaCl, 0.1% CHAPS, 1.5% sucrose, and 10 mM DTT. Ninety-six and a half microliters 
of enzyme in buffer were added per well in a black Corning 3356 96-well assay plate. Test 
compounds were serially diluted in dimethyl sulfoxide (DMSO) and plated in duplicate or triplicate 
in a Corning 3357 transfer plate. Test compound was added to assay plates in 1 µL aliquots per 
well using a BiomekFX and mixed 10 times. Compound and enzyme mixture was incubated at 
37°C for 5 minutes.  The BiomekFX was then used to add and mix 2.5 µL of the AFC substrate, 
Ac-DEVE-AFC (0.4 mM), in DMSO from a transfer plate to the assay plate for a total assay volume 
of 100 µL in the assay plate.  Fluorescence from free AFC was read at 37°C every 5 minutes over 
an hour using a Clariostar reader (λex = 400 nm, λem = 505 nm). GraphPad Prism (v9) was used to 
calculate the IC50 by fitting the dose-response data with four parameter variable slope nonlinear 
regression.218 The 40 minute time point was reported, consistent with reported literature.195,219–221 
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3.2.4 Co-crystallization of Cas-3 with Select Pentapeptide Inhibitors 
Two different previously published well conditions were used to generate co-crystals of 
Caspase-3 and select inhibitors.222,223 500 µL of Caspase-3 (100 mM Tris pH 8.0, ~175 mM NaCl, 
and 10% glycerol) at 0.5 mg/mL was incubated with 500 µM inhibitor for 30 minutes on ice to 
allow for covalent bond formation. The solution was then concentrated to 4 mg/mL and protein 
concentration was tested using the A280 on the nanodrop. Cas-3-ligand crystals were generated by 
mixing equal amounts of protein with well solution containing either Condition 1: 15% PEG 6000, 
5% glycerol (v:v), 100 mM sodium citrate pH 5.3, 10 mM DTT, and 30 mM NaN3 or Condition 2: 
16% PEG 6000, 5% glycerol, 100 mM sodium citrate pH 6.5, and 10 mM DTT. Plate-like crystals 
grew within 24-48 hours and were cryoprotected with well solution supplemented with 10% PEG 
6000 prior to flash freezing. 
3.2.5 X-ray Data Collection 
Diffraction data was collected at IMCA-CAT beamline 17-ID at the Advanced Photon 
Source (APS), Argonne, Illinois, USA. Collection was completed at 100 K using radiation of 
wavelength 1.00 Ångstroms and a Dectris Eiger2 9M detector. Data was processed using autoProc 
and re-scaled using aP_scale using I/sigma (>2), R-factor (<.4), and completeness (>90%) as 
criteria, with a minimum of two of the three criteria being met to determine the proper resolution 
range.201 
3.2.6 Data Processing and Structural Refinement 
The structure of Cas-3 co-crystallized with Ac-VDVAD-CHO, PDBid: 2H65, was used as 
a search model for molecular replacement with Phaser.202,224 The monoclinic and orthorhombic 
crystal forms were found to contain a homodimer in the asymmetric unit with the monomer being 
composed of the small (p12) and large (p17) subunits. Iterative rounds of refinement and model 
building were carried out using Phenix203 and Coot204. Pentapeptide inhibitors were modeled into 
the electron density using Coot and the covalent bond between Cys163 and the P1 aspartic acid 
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was constrained by adding a link record to the PDB file prior to subsequent round of refinement. 
The bond between Cys163 (atom name SG) and P1 (atom name C) was restrained to 1.5Å with a 
sigma of 0.5 and the thioester carbon center geometry was restrained to be planar. Refined 
structures were validated with MolProbity.206 Table 3.1 was compiled with data from the data 
collection and use of Phenix for assessment of structure quality.207 Atomic coordinates and 
reflection data for 10 pentapeptide co-crystal structures with Cas-3 were deposited into the Protein 
Data Bank and coordinates will be made available upon pulication.129 PDB accession codes are 
included in Table 3.1. 
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Table 3.1 Data Processing and Refinement Statistics for Cas-3 
 
 
Data collection and processing








Resolution range 43.28  - 2.4             
(2.486  - 2.4)
43.28  - 2.4                  
(2.486  - 2.4)
42.35  - 1.67 
(1.73  - 1.67)
43.2  - 1.9            
(1.968  - 1.9)
56.22  - 1.75              
(1.813  - 1.75)
Space group P 1 21 1 P 1 21 1 P 21 21 21 P 1 21 1 P 63










a, b, g (°) 90 90.608 90 90 90.608 90 90 90 90 90 90.926 90 90 90 120
Total reflections 41458 (4026) 41458 (4026) 127065 (10909) 68436 (6860) 112174 (11468)
Unique reflections 21706 (2160) 21706 (2160) 64162 (5853) 41044 (4176) 56317 (5772)
Multiplicity 1.9 (1.9) 1.9 (1.9) 2.0 (1.9) 1.7 (1.6) 2.0 (2.0)
Completeness (%) 98.36 (98.18) 98.36 (98.18) 97.13 (89.45) 95.42 (97.80) 95.92 (98.68)
Mean I/sigma(I) 4.44 (2.19) 4.44 (2.19) 14.75 (2.46) 11.02 (2.30) 17.08 (4.43)
Wilson B-factor 30.39 30.39 21.75 30.54 22.28
R-merge 0.1175 (0.3766) 0.1175 (0.3766) 0.02208 
(0.2335)
0.03228 (0.419) 0.0208 (0.1348)






CC1/2 0.965 (0.718) 0.965 (0.718) 0.999 (0.921) 0.999 (0.731) 0.999 (0.943)
CC* 0.991 (0.914) 0.991 (0.914) 1 (0.979) 1 (0.919) 1 (0.985)
Reflections used in refinement 21693 (2161) 21693 (2161) 64072 (5853) 41013 (4176) 56310 (5772)
Reflections used for R-free 1107 (133) 1107 (133) 3259 (283) 1991 (186) 2816 (284)
Rwork 0.1878 (0.2272) 0.1878 (0.2272) 0.1831 (0.2943) 0.1945 (0.2817) 0.1668 (0.1945)
Rfree 0.2515 (0.3158) 0.2515 (0.3158) 0.2099 (0.3383) 0.2310 (0.3268) 0.2018 (0.2507)
CC(work) 0.946 (0.877) 0.946 (0.877) 0.969 (0.907) 0.963 (0.867) 0.969 (0.916)
CC(free) 0.919 (0.655) 0.919 (0.655) 0.962 (0.844) 0.935 (0.789) 0.959 (0.844)
# of non-hydrogen atoms 3915 3915 4130 3945 4150
   macromolecules 3804 3804 3835 3815 3884
   ligands 6 6 6 0 6
   solvent 105 105 289 130 260
Protein residues 473 473 472 475 478
R.m.s. deviations
   Bonds (Å 2) 0.008 0.008 0.008 0.008 0.007
   Angles (°) 1.09 1.09 0.93 1 0.95
Ramachandran
   Favored (%) 96.48 96.48 98.04 98.26 97.85
   Allowed (%) 3.52 3.52 1.96 1.74 2.15
   Outliers (%) 0 0 0 0 0
Rotamer outliers (%) 0 0 0 0.24 0
Clashscore 5.18 5.18 4.99 5.94 3.37
Average B-factor 30.12 30.12 24.23 34.56 24.96
Structure solution and refinement
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Table 3.1 Data Processing and Refinement Statistics for Cas-3, Continued 
 
 
Data collection and processing
PDB ID 7RNC 7RND 7RNE 7RNF 7RNG
Ligand Ac-VDVVD-CHO Ac-VDPVD-CHO Ac-YKPVD-CHO Ac-VDKVD-CHO Ac-ITAKD-CHO
Resolution range
42.36  - 1.933 
(2.002  - 1.933)
40.9  - 2.15 
(2.227  - 2.15)
63.38  - 2.73 
(2.828  - 2.73)
33.54  - 2.111 
(2.187  - 2.111)
32.31  - 2.55 
(2.641  - 2.55)
Space group P 21 21 21 P 1 21 1 P 21 21 21 P 1 21 1 P 63










a, b, g (°) 90 90 90 90 90.45 90 90 90 90 90 91.137 90 90 90 120
Total reflections 82243 (8347) 57475 (5421) 30366 (2948) 59043 (6105) 37935 (3760)
Unique reflections 41470 (4144) 29662 (2924) 15215 (1471) 30149 (3101) 19022 (1882)
Multiplicity 2.0 (2.0) 1.9 (1.9) 2.0 (2.0) 2.0 (2.0) 2.0 (2.0)
Completeness (%) 96.76 (98.69) 97.35 (96.79) 99.43 (99.59) 95.41 (99.81) 99.88 (100.00)
Mean I/sigma(I) 7.14 (2.34) 12.15 (4.49) 10.85 (2.95) 9.26 (2.28) 9.28 (3.73)


















CC1/2 0.974 (0.942) 0.998 (0.931) 0.998 (0.946) 0.998 (0.861) 0.987 (0.776)
CC* 0.994 (0.985) 0.999 (0.982) 1 (0.986) 0.999 (0.962) 0.997 (0.935)
Reflections used in refinement 41305 (4144) 29638 (2924) 15156 (1471) 30132 (3102) 19012 (1882)
Reflections used for R-free 2060 (187) 1421 (145) 737 (76) 1497 (179) 908 (97)
Rwork 0.2343 (0.2855) 0.1687 (0.2033) 0.1904 (0.2870) 0.1782 (0.2066) 0.1774 (0.2431)
Rfree 0.2840 (0.3121) 0.2218 (0.2778) 0.2535 (0.3852) 0.2368 (0.2630) 0.2416 (0.2911)
CC(work) 0.932 (0.927) 0.965 (0.935) 0.961 (0.890) 0.966 (0.924) 0.955 (0.834)
CC(free) 0.905 (0.855) 0.945 (0.806) 0.920 (0.796) 0.926 (0.814) 0.939 (0.833)
# of non-hydrogen atoms 4038 4021 3798 3977 3899
   macromolecules 3822 3870 3765 3847 3811
   ligands 6 0 0 6 0
   solvent 210 151 33 124 88
Protein residues 476 475 471 472 474
R.m.s. deviations
   Bonds (Å 2) 0.008 0.007 0.008 0.008 0.008
   Angles (°) 0.99 1.37 0.95 0.95 0.95
Ramachandran
   Favored (%) 98.71 97.41 96.95 97.61 98.05
   Allowed (%) 1.29 2.16 3.05 2.39 1.95
   Outliers (%) 0 0.43 0 0 0
Rotamer outliers (%) 0 0.24 0.97 0 0.48
Clashscore 5.4 3.92 7.91 4.57 5.41
Average B-factor 26.79 28.92 42.48 34.62 38.91
Structure solution and refinement
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3.3 Results and Discussion 
3.3.1 Confirming Protein Purification and Crystallographic Methods 
Expression, isolation, purification, and co-crystallization with peptides of human Cas-3 
using a bacterial expression system has been achieved by previous researchers.225 The target was 
new to the Finzel laboratory and therefore the first objective was optimizing the protein expression 
and determining the optimal conditions for crystallography of the purified protein. Inoculation of 
the large culture from the overnight culture was slow to reach mid-log phase (OD600=0.5-0.7) as it 
took approximately 8 hours (relative to 3 hours observed for hMDH1 discussed in Chapter 2) and 
yielded a small cell pellet following centrifugation (~2 g/L). Caspase is a proteolytic enzyme and 
therefore could be self-cleaving leading to cellular death resulting in slower growth. To potentially 
circumvent this adverse effect and increase the speed of cell growth, an additional growth step, 
suggested in a different protocol, was added prior to inoculating the large culture and the media 
was switched to 2X TY media that has been used for other Caspases.217 The additional growth step 
decreased the time needed to reach mid-log phase and increased the size of the resulting cell pellet 
(~5 g/L). Isolation of Cas-3 involved using the His-tag and purification followed with an ion-
exchange column to yield pure protein that was confirmed in the enzymatic activity assay by Jessica 
Strasser to be equal or slightly more active than the purchased protein used in the Walters’ 
laboratory.  
Initial efforts in crystallography involved screening previously published conditions for 
Caspase-3 co-crystals. The initial attempts involved incubating the published protein concentration 
(4 mg/mL or ~140 µM) with a 20-fold molar excess of ligand (2.8 mM) on ice for 30 minutes to 
ensure covalent linkage prior to setting up crystal trays with varying conditions. Previous published 
conditions with this incubation step and Ac-VDVAD-CHO did not lead to any crystal growth. 
Using a 50 mM stock solution of peptide dissolved in DMSO and targeting 2.8 mM final peptide 
concentration, meant that the ratio of protein:ligand needed to be ~ 17:1 resulting in a final DMSO 
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concentration (v:v) of 5.5%. Previous enzymatic activity work had shown that the Caspase family 
of enzymes lose enzymatic activity with increasing concentration of DMSO.195,219–221 To decrease 
the amount of concentration of DMSO, ligand was diluted to 0.5 mg/mL and incubated with the 
same molar excess of peptide inhibitor and incubated on ice for 30 minutes. Following incubation, 
the protein-peptide complex was concentrated to 4 mg/mL using a centrifugal filter unit. The 
incubation at dilute concentration and subsequent concentration decreased the DMSO 
concentration and led to crystal growth. Two conditions, described in the methods as Condition 1 
and Condition 2, were found to generate plate-like crystals that grew within 24-48 hours (Figure 
3.2). The fast growth observed generated thin plates that were able to gain a little more three-
dimensional character with time. Efforts to slow the growth included varying protein, PEG, and 
DTT concentration and varying the pH of the citrate buffer, but no combination greatly increased 
the 3-D character of the crystal or changed the morphology. Freshly solubilized DTT was found to 
be critical to crystal growth. To establish Cas-3 co-crystallization in the Finzel laboratory, co-
crystal complexes with previously published ligands Ac-VDVAD-CHO (PDBid: 2h65), Ac-
LDESD-CHO (PDBid: 3edq), and Ac-DEVD-CHO (PDBid: 1pau) were grown and diffraction data 
collected. The structures were found to contain electron density for the peptide inhibitor bound to 
Cys163 of each monomer of the asymmetric unit (Figure 3.3) and mapped well onto previously 
published structures with equal or improved resolution (Figure 3.4). The crystallographic data and 
refinement statistics for these structures are not included in the chapter as the structures are not 
novel and were meant only as a proof of concept to show collaborators that we were ready for new 






Figure 3.3 Structure of Ac-DEVD-CHO and Caspase-3 
A) Omit map of covalently bound Ac-DEVD-CHO. Map mesh vectors lying more than 1.8 Å 
from the peptide are hidden. B) Dimeric structure of Caspase-3 with two bound instances of the 
ligand shown in cyan.  
A B
 
Figure 3.2 Microscope Image of Cas-3 Crystal Morphology 
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3.3.2 Crystallographic Data of 10 Novel Caspase-3 Co-crystal 
Structures 
A total of 10 crystal complexes were generated, solved, and deposited for Caspase-3 co-
crystallized with pentapeptides (Table 3.1). The structures are all monoclinic, orthorhombic, or 
hexagonal and exhibit one of three space groups (P21, P212121, P63). Resolution of the structures 
varies from 1.66-2.73 Ångstroms, but the resolution of the structures does not have any correlation 
on the space group or Ki of the pentapeptide. The Rwork for the majority of the structures is less than 
0.2 which is better or comparable than structures published at the same resolution (Ac-VDVVD-
CHO, PDBid: 79NC, has a higher than expected Rwork of 0.238).129 The majority of the Rfree values 
 
Figure 3.4 Overlay of Ac-DEVD-CHO Structure to Previously Published Structure 
Overlay of the co-crystal structure of Caspase-3 with Ac-DEVD-CHO at a higher resolution 
shown in purple with the previously published structure with the same ligand (PDBid: 1pau) in 
orange. Global RMSD for superposition is 0.286 Å. 
 
 65 
are within 5% of the Rwork values showing that the models were properly fitted into the working set 
of reflections.226 While the structures vary in their resolution, space group and R-factors, they have 
several observed characteristics that are maintained between them. The unit cell is composed of a 
dimer of the basic biology subunit, p17 and p12 subunits. The p17 subunit and p12 subunit combine 
to form the expected loops (L1, L2, L3, and L4) that form the substrate binding pocket. All 
structures contain two instances of the pentapeptide that has the aspartic acid covalently bonded to 
Cys163. The bond formation was forced in the model building and refinement in Coot and Phenix, 
respectively, but electron density supports the disulfide bond (Table 3.2). The pentapeptides are 
labeled Ac-XXXXX-CHO and the formation of the covalent bond between Cys163 and the aspartic 
acid at P1 causes the cleavage and loss of the CHO functional group. The molecule names were 
kept in this format for deposition into the PDB (even though the CHO is not present) to retain the 
name of the molecule that was synthesized and co-crystallized with Cas-3. The thioester carbon 
geometry was forced trigonal planar, as this is the expected geometry, using planarity restraints for 
refinement in Phenix. The N-terminus of the pentapeptides have the nitrogen acetylated, but 
electron density for many of the structures does not support the modification and therefore the 











Table 3.2 Ki and Omit Maps for Novel Pentapeptides 























1Ki values are from Caspase-3 enzymatic activity assay. Work completed by Jessica Strasser. 




3.3.3 Comparison of P3-Variant Series 
A series of pentapeptides varying at P3 (reminder P1 is the amino acid linked to the 
catalytic cysteine) were synthesized and their co-crystal structures with Caspase-3 were generated. 
The structural data would aid in comparison of conformational differences in the protein and 
substrate as a means of understanding potency and selectivity because of various P3 amino acids. 
Understanding the binding modality of the P3-variants should guide de novo peptide inhibitor 
design. Co-crystal structures were generated for 7 different P3-variant pentapeptides with a variety 
of amino acids used at P3: proline, valine, arginine, lysine, phenylalanine, and two unnatural amino 
acids: acetyl lysine and ornithine (Table 3.3). The R-groups of the P3-variants gives an interesting 
population for structure activity relationships as it contains charged, polar, hydrophobic, and 

















Table 3.3 Structure of P3-Variants 
 























































3.3.3.1 Hydrogen Bonding through Peptide Backbone 
In superimposing the 7 structures onto a published reference structure of Caspase-3 co-
crystallized with Ac-VDVAD-CHO (PDBid: 2H65), little backbone movement is detected between 
the structures except for Ac-VDPVD-CHO. The pentapeptide Ac-VDPVD-CHO will be discussed 
in more detail in a subsequent section. The Ca’s of the pentapeptides map well onto each other 
with some slight deviation in atomic position of the Ca of P5 (Figure 3.5). The variation of the P3 
amino acid does not cause a change in the positioning of the inhibitor within the substrate binding 
site. The pentapeptides are able to interact through a series of conserved hydrogen bonds involving 
the main chain with the active site of Cas-3 (Figure 3.6). The carbonyl of P1 peptide can hydrogen 
bond with the amide of Cys163 and the amide of Gly122 of L1. The majority of the hydrogen bonds 
of the main chain of the pentapeptides involve L3. The amide of P1 hydrogen bonds with the 
carbonyl of Ser205. Arg207 engages the pentapeptide backbones in a variety of ways: a 
guanidinium nitrogen of arginine hydrogen bonds with the carbonyl of P2, the nitrogen of the 
arginine backbone interacts with the carbonyl of P3, and the carbonyl of the arginine main chain 
hydrogen bonds to the amide of P3. The side chain hydroxyl group of Ser209 can hydrogen bond 
with the amide and carbonyl of P5, and the amide of Ser209 also interacts with the carbonyl of P5. 
P4 makes only a single contact with the pentapeptide main chain: a hydrogen bond between the 
carbonyl of Phe250 and the nitrogen of P4. The hydrogen bond with Phe250 is not observed in the 
Ac-VDRVD-CHO structure, discussed in more detail below. The peptides all exhibit similar 
inhibition in the enzymatic activity assay which could mean that conformation of the backbone that 
maintains this hydrogen bonding network is potentially more important than the sequence of the 
amino acids within the pentapeptides. Successfully engaging Arg207 of L3 is important to 




Figure 3.5 Overlay of the Backbone of the P3-Variant Pentapeptides 
The main chain of the P3-variant pentapeptides (Ac-VDPVD-CHO is not shown) covalently 
bonded to Cys163. The structures were superimposed onto reference structure Ac-VDVAD-











Figure 3.6 Hydrogen Bonding Network of P3-Variant Main Chain with Cas-3 
3.3.3.2 L4 Loop Shows Small Shift  
Looking at the L1, L2, L3, and L4 loops of the P3-variant Cas-3 co-crystal structures, little 
movement of the loops is detected. The molecules do not appear to cause a significant change in 
the tertiary structure or protein folding. The Ac-VDRVD-CHO causes a slight shift in L4 which is 
pushed 1.5-1.8 Å away from the substrate binding site thus increasing the exposed surface area 








the distance between the acceptor and donor is 4.5 Å – too far for an energetically meaningful  
hydrogen bond with the protein (Figure 3.8). Ac-VDRVD-CHO does have slightly worse inhibition 
which could be explained by the loss of this hydrogen bond. The shift of L4 cannot be directly 
attributed to arginine at P3 as the arginine R-group does not extend towards L4 but rather lies over 
the pentapeptide backbone. 
 
Figure 3.7 Small Shift in L4 Loop of Ac-VDRVD-CHO Structure 
Overlay of the P3-variants (Ac-VDPVD-CHO is not included) with the L1, L3, and L4 loops. 











Figure 3.8 Hydrogen Bonding Network of Ac-VDRVD-CHO Backbone 
3.3.3.3 Proline in Ac-VDPVD-CHO Causes Movement of P4 and P5 
Looking at the Ki values we see that a majority of the modifications do not cause any 
change in the inhibition of Cas-3. This is not the case if a proline occupies P3. Substituting proline 
for a valine results in a 2-log fold reduction (34 nM vs 3519 nM) in inhibition. The pyrrolidine ring 
of proline restricts the phi angle and therefore causes the subsequent amino acids to be displaced 
(Figure 3.9). This pushes P4 and P5 (as a result of P4) specifically the aspartic acid R-group of P4 
out towards the C and C a of P5 of the non-proline structures. This shift causes a loss of several 
hydrogen bonds of the pentapeptide backbone to the L3 loop which could explain the decrease in 
inhibition. Maintenance of the relative atomic positions of the pentapeptide backbone is paramount 









Figure 3.9 Hydrogen Bonding Network of Ac-VDPVD-CHO Backbone 
3.3.3.4 Hydrogen Bonding Differences Resulting from P3 
The majority of the interactions of the pentapeptide series with Caspase-3 involves 
hydrogen bonding of the backbone with L1, L3 and L4, as discussed in a previous section (Figure 
3.6). To gain a better understanding of the structure-activity relationship of the P3 modifications, 
the effect of the R-group on the hydrogen bonding network was compared (Figure 3.10). Of the 
seven different R-groups tested, four (Ac-VDVVD-CHO, Ac-VDFVD-CHO, Ac-VDKVD-CHO, 
and Ac-VD(Orn)VD-CHO) are only able to interact with Phe207 of L3 through the amide and 
carbonyl of P3. The guanidinium nitrogen atoms of Ac-VDRVD-CHO hydrogen bond 








through the carbonyl because the amide is rotated away from the carbonyl on Phe250. The only R-
group that can engage any other amino acid is the acetyl-lysine P3-variant: the acetyl oxygen can 
form a hydrogen bond with the sidechain oxygen of Ser65. This could be a new interaction that 
could be targeted in new inhibitor design.  
 
Figure 3.10 Comparison of Different Hydrogen Bonds with Different P3 Amino Acids 
3.3.4 Non-canonical Peptide Structure Activity Relationship 
The canonical sequence of Caspase-3 inhibitors is D-X-X-D and therefore to sample a 
broader amino acid profile, non-canonical peptides were co-crystallized with Caspase-3. The 










bond formation with the catalytic cysteine but do not contain an aspartic acid at P4 thus making 
them non-canonical. The use of the non-canonical sequences is important to new peptide design as 
it highlights the structural role of aspartic acid at P4 on the observed inhibition. Differences in 
protein flexibility and inhibitor binding modality can be compared for substitutions to amino acids 
other than the canonical aspartic acid to guide future inhibitor design. 
3.3.4.1 Ac-ITAKD-CHO vs. Ac-ITV(Dab)D-CHO 
The pentapeptides Ac-ITAKD-CHO and Ac-ITV(Dab)D-CHO are very similar in their 
sequence but exhibit large differences in their inhibition of Cas-3 enzymatic activity. 2,4-
diaminobutryic acid (Dab) is an unnatural amino acid that mimics a lysine R-group but contains 
one less methylene. Valine and alanine are both hydrophobic amino acids of comparable size. 
Therefore, the two sequences would be expected to interact very similarly with their target, Cas-3. 
While their atomic composition is very similar, there is a considerable difference in their inhibition 
on enzymatic activity (Table 3.2). This near ten-fold decrease in inhibition (moving from Ac-
ITAKD-CHO to Ac-ITV(Dab)D-CHO) can be explained by comparing the co-crystal structures. 
The main chain of P1-P3 map well onto each other but differences are noted in the position of the 
P4 and P5 loop. The R-group on P2 of each pentapeptide extends towards L4 where the primary 
amine of lysine and Dab is within proximity of Phe256 and engages in pi-cation interactions.  The 
Ca’s of Phe250-Ala258 in the L4 loop shift 1.0-2.2 Å to accommodate the larger amino acid 
(lysine) at P2 exemplifying the induced-fit upon ligand binding (Figure 3.11). P4 and P5 of Ac-
ITAKD-CHO follow the movement of L4 to allow for the peptide backbone to continue engaging 
in the hydrogen bonding network. The molecules exhibit similar hydrogen bonding networks, but 
Ac-ITV(Dab)D-CHO the carbonyl of P5 can engage the amide and carbonyl of Ser209 (Figure 
3.12). Where positioned, the P5 nitrogen can interact with the oxygen of the backbone of Phe250. 
Since Ac-ITV(Dab)-D is able to make more total hydrogen bonds, it might be assumed that it would 
bind tighter to Cas-3 than the other non-canonical sequence, but this is not the case. The longer R-
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group of lysine is causing a different induced-fit than the other ligands tested. The conformation of 
the L4 loop in the Ac-ITAKD-CHO may be in a lower energy conformation (protein is more stable) 
that is stabilized by the addition of the peptide. Generating molecules which cause this movement 
in L4 could increase affinity and therefore potency.  
 
Figure 3.11 Induced-Fit by Larger P2 R-Group Causes Shift in L4 
Superimposing the structures of Ac-ITAKD-CHO (fuchsia) and Ac-ITV(Dab)D-CHO (gold). 


















3.3.4.2 Ac-YKPVD-CHO: Absence of Density for P4 and P5 
Ac-YKPVD-CHO is only modeled from P1 to P3 with nothing modeled for P4 and P5 as 
there was no electron density in the Fo-Fc map and modeling in the P4 and P5 peptides caused 
negative difference map peaks in the subsequent round of refinement. The peptide is clearly bound 
(Table 3.2) and the rest of the peptide would be present (no precedence for cleavage of the 
pentapeptide) so in crystallography this portion is deemed disordered. Crystallographic disorder 
describes atoms, molecules, or chains where translational periodicity, atomic positions between 
unit cells are related by a translational matrix, is not observed. In other words, the P4 and P5 
residues adopt a variety of conformations in different unit cells and therefore atomic positions in 
the model cannot be defined. As discussed above with the proline P3-variant, proline causes a shift 
in the backbone of the protein due to the constraint on the phi angle. The pentapeptide, even with 
 
Figure 3.12 Hydrogen Bonding Comparison Between Ac-ITAKD-CHO and Ac-
ITV(Dab)D-CHO 

























its relative poor affinity, is able to covalently bond to Cys163. The lack of affinity highlights the 
importance of the hydrogen bonding network in P4 and P5 in which Ac-YKPVD-CHO is unable 
to engage. Design of a potent inhibitor should avoid placement of proline at P3 and maybe in the 
pentapeptides as a whole.  
3.3.4.3 Molecular Replacement and Refinement Issues with Two Structures with 
Unique Cell Parameters 
Generation of co-crystal structures were attempted with additional non-canonical peptides: 
Ac-ITV(Orn)D-CHO and ITVKD-CHO. Diffraction data was collected on both of these structures 
but the processing of the diffraction pattern images gave new unit cell parameters (parameters for 
Ac-ITV(Orn)D-CHO): 97.559, 66.67, 131.929, 90, 101.352, 90 (a, b, c, a, b, g). Comparing these 
values to that of the refined structures (Table 3.1) we see that the length of the a-axis and c-axis are 
considerably longer. Molecular replacement using PDBid 2H65 for Ac-ITV(Orn)D-CHO placed a 
tetramer of the biological unit within the unit cell instead of the dimer observed in previously 
published structures and the other successfully generated structures in the Finzel laboratory. The 
additional dimer is not related by translational matrices and therefore resides in the asymmetric 
unit. Figure 3.2 shows that the initial morphology of the Caspase-3 co-crystals is thin plate-like 
crystals that can grow some greater three-dimensional character with time. The issue with viewing 
plate-like crystals using a microscope is determining if the plate is singular or contains multiple 
plate-like crystals stacked on top of each other. Twinning in crystallography refers to neighboring 
domains that are mutually reoriented according to a specific symmetry operation relating to the 
crystal lattice that does not belong to the symmetry operations relating to the space group. Twinning 
can usually be easily detected upon inspection of the diffraction pattern (closely related spots that 
vary in intensity), but current software can also be used to determine crystal twinning or presence 
of twin laws. Viewing the diffraction pattern and using the software present in Phenix, the poor 
data processing issues are not a result of twinning. The diffraction pattern has an abnormally large 
number of spots present on the detector which suggests that the assumed single plate-like crystal 
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was rather a composite of multiple plate like crystals stacked on top of each other which are not 
related by a crystal lattice symmetry operator (Figure 3.13). This issue was not observed in any of 
the other structures, and no conclusion to the overlapping plate morphology can be attributed to the 
ligand, the protein, or the ligand-protein complex. Decreasing the aperture of the beam and finding 
areas on the crystal where fewer reflections are observed (likely near the edges) should hopefully 
avoid this issue in the future.  
 




3.3.5 Inability to Generate Co-crystal Structures with Non-Peptidic 
Inhibitors of Cas-3 
In brief, the crystallization conditions used for the pentapeptide inhibitors were applied to 
a series of non-peptide like molecules. Two of the molecules were synthesized by Dr. Gurpreet 
Singh in Dr. Michael Walters’ laboratory in the Institute for Therapeutics Discovery and 
Development at the University of Minnesota and have not been published, and therefore, the 
structure of these molecules will not be disclosed in this chapter. The synthesized molecules are 
non-peptide-like molecules and pose particular interest as they would have higher potential of 
crossing the blood-brain-brain and reaching and acting on their target, Caspase-2. The molecules 
using the two described crystallization conditions did not lead to crystals that diffracted (some very 
small micro-crystalline material was observed, but it did not grow to a size that was usable). The 
established method (incubation of ligand with dilute protein followed by concentrating of the 
protein-ligand complex) and conditions might only be conducive to peptide inhibitors. Future work 
on the Caspases in the Finzel laboratory will need to discover conditions that can work across all 
inhibitors.  
3.4 Conclusion 
This chapter has taken an in-depth look at the structure of Caspase-3 and the associated 
activity relationship of 10 pentapeptides. The pentapeptides tested covered a variety of 
modifications to the peptide at P3 and also examined a series of peptides that lacked the aspartic 
acid at P4 making them non-canonical peptide inhibitors. Examination of the P3-variant co-crystals 
structure shows that the pentapeptide backbone is very consistent amongst the 7 variants tested 
except for Ac-VDPVD-CHO. The binding of these peptides is stabilized by a series of hydrogen 
bonds between the main chains of the peptides and L1, L3, and L4. Arg207 makes several hydrogen 
bonds with the peptides and therefore engagement of this amino acid appears to be essential to 
inhibitory potential. The non-proline P3-variants show little change in inhibition of Caspase-3 even 
though the R-groups can engage in different hydrogen bonds which highlights that the R-group of 
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P3 is not critical to inhibition. Proline has a constrained phi angle that deviates from the angles 
observed in non-proline structures and this deviation causes the shift of P4 and P5 which explains 
the drastic loss in inhibition observed. Structural biology efforts have shown that maintenance of 
the hydrogen bonding network of the peptide backbone in P3, P4 and P5 is critical to the potency 
of the pentapeptides. Three non-canonical pentapeptides (lacking aspartic acid at P4) were co-
crystallized with Caspase-3. The longer P2 R-group of Ac-ITAKD-CHO is able to push L4 away 
from the substrate binding site. The peptide has comparable affinity to the P3-variants and therefore 
this induced-fit could be forcing Cas-3 into a lower, more-energetically favored protein fold. The 
10 novel pentapeptide Cas-3 co-crystal structures will hopefully be used in homology modeling 
and structural comparison to Cas-2 co-crystal structures leading to a potent and selective inhibitor 


















4. Computational Efforts Towards the Design of THIQ-
Saccharide Conjugates as Inhibitors of CD44 
 
 
Portions of this work have excerpted from published work. 
 
Table 4.1 was remade with permission from: Li-Kai, L. Discovery of Small Molecule Inhibitors of 
Hyaluronan Binding at Cell Surface Receptor CD44. Thesis Dissertation. June 2015 
 
 
Author Contributions: Dr. Soma Maitra in Dr. Gunda Georg’s laboratory at the University of 
Minnesota completed the synthesis and characterization of the THIQ-Monosaccharide conjugate. 
Scheme 4.1 depicts the synthetic scheme to generate the conjugate molecule and was made by Dr. 
Soma Maitra in ChemDraw. The synthesis is not described in any detail. 
 
 
A detailed background on the role of the extracellular matrix in cancer, the function of the signaling 
molecule HA, a comparison of the hyaldherins, an in-depth look at the known structural biology 
surrounding CD44 and its interaction with HA, and a look at antagonism of CD44-HA interactions 




4.1.1 Rational Behind THIQ-Oligosaccharide Conjugate Molecules 
Previous biophysical and structural biology studies in the Finzel lab resulted in the 
identification of a series of small molecules containing a tetrahydroisoquinoline (THIQ) moiety 
that bind in an inducible small-molecule subsite of CD44 HABD with sub-millimolar affinity.88 A 
Maybridge Ro3 Diversity Fragment library of 1000 compounds was screened in a single point 
immobilized-HABD surface plasmon resonance (SPR) assay with a cutoff threshold of 
approximately 10 RU to achieve an initial hit rate of 4%.88 Hit fragments were then screened in a 
dose-response SPR assay to find compounds that could be fitted using a 1:1 binding isotherm.88 
Molecules that fit this binding isotherm were then subjugated to co-crystallization with mCD44 and 
structures were generated for five of these molecules.88 Two of the small molecules, an aniline-
based compound and a THIQ-based compound, were of particular interest for their binding location 
and induced conformational changes in the protein (Table 4.1). The addition of the exocyclic 
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nitrogen present in the aniline-based compound to the THIQ moiety led to a 7-fold improvement 
in binding affinity.88 In comparison of the apo structure to the small-molecule induced structure, 
Arg155 and Asn29 rotate to create pi-stacking above and below the aromatic ring while Glu41 
moves away from Arg82 to form an H-bond with the THIQ secondary amine and to form a 
hydrogen bond with the reoriented Asn29 (Figure 4.1). The exocyclic nitrogen on the THIQ moiety 
can form a hydrogen bond with the backbone oxygen of Val30 and two well-anchored water 
molecules (Figure 4.1). Crystal structures of a 5-amino-THIQ and 8-amino-THIQ shows some 
flexibility in the orientation of the THIQ. The endocyclic nitrogen in both structures can hydrogen 
bond to Glu41 (alternate Glu41 rotamers) by adopting different ring puckers (Figure 4.1). An 8-
amino-THIQ scaffold was selected over the initial 5-amino-THIQ hit compound as the 5-amino 
compound introduces a chiral center which decreases the synthetic opportunities and the 8-amino-








Figure 4.1 Conformational Changes in mCD44 Induced by THIQ 
5-amino-THIQ induces conformational changes in Arg155, Asn29 and Glu41 to bind in a site 
just below the HA binding groove in CD44. The apo structure is colored in salmon (PDBid: 
4mrd) and the bound structure is colored in white (PDBid: 5mrg). Conformational differences 








Table 4.1 Fragment Evolution of THIQ Moiety 
 
1The numbering of atom position is provided for the 5-amino- and 8-amino-THIQ compounds 
to help clarify the difference between the analogs. The endocyclic nitrogen of the isoquinoline 
is atom 2. 
2Ligand efficiency, (–RT lnKD)/(number of non-hydrogen atoms), was calculated based on the 
affinity of ligands to hHABD in kcal mol-1. 
3KD and IC50 values were measure using the two surface plasmon resonance assays: the 
immobilized HABD SPR assay and the immobilized HA SPR assay, respectively. 
 
A series of 8-amino compounds were synthesized with extending length from N2 and were 
found to exhibit increasing potency and inhibition with further extension towards the HA groove 
(Table 4.1).227 A N-methylpropanamide extension from N2 of 8-amino THIQ was purchased from 
Enamine. The three carbon linker extends towards and into the hyaluronan binding groove with the 
nitrogen lying in almost the same position as the 3’ hydroxyl of the Glc-5 of HA in the co-crystal 
structure of mCD44 with an HA-oligosaccharide, PDBid: 2JCR (Figure 4.2) As a proof of concept, 
Structure1 LE2 IC50 (mM)
3 PDBid:
hHABD mHABD hHABD
0.31 8.5 ± 1.2 6.4 ± 1.0 No Inhibition 4MRE
0.29 6.9 ± 1.5 11.2 ± 4.5 27 4MRF
0.4 0.9 ± 0.2 1.1 ± 0.2 6.7 4MRG
0.36 1.2 ± 0.2 No Data 7.5 5BZI
0.26 0.6 ± 0.4 No Data 3.1 5BZO






























a pyran compound with a three-methylene and one oxygen atom linker connected to N2 of the 8-
amino-THIQ was synthesized in the ITDD at the University of Minnesota.227 The compound allows 
for proper positioning of the THIQ moiety and the pyran reaches into the Glc-5 subsite but does 
not superimpose directly onto Glc-5.227 The findings suggest that the three-carbon linker leading 
into Glc-5 should allow for proper conformations of the THIQ and Glc moieties to allow for 
improved binding affinity. 
 
Figure 4.2 Overlay of THIQ-Methylpropanamide and HA-Oligosaccharide Structures 
Overlay of co-crystal structures of CD44 (white cartoon and white surface) with THIQ-N-
methylpropanamide conjugate in blue (PDBid: 5BZO) and HA-oligosaccharide in orange 
(PDBid: 2jcr). 
4.1.2 Fragment Linking to Increase Potency 
 In the drug discovery process, one approach to improving the potency of fragment 
molecules involves linking two fragment molecules to form a larger non-fragment like molecule.228 
The approach is contingent on discovery of multiple hit fragments whose structure can be 
determined using structural biology approaches and their binding modality places the fragments 
within different but closely located sub-sites within the protein binding site.228 Linking of two 
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fragments should be greater than the sum of the binding energies of the two fragments and instead 
a “superadditivity” or “positive cooperativity” should be observed.228,229 This principle is described 
by Jencks in Equation 4.1.229 The Gibbs free energy of binding of the linked fragments is quantified 
as the free energy of each individual fragment with the addition of ΔGS which takes into account 
changes in translational and rotational entropy as a result of the introduction of the linker.229,230 
Equation 4.1 can be rewritten to describe the dissociation constant KDAB for a linked fragment A-B 
in Equation 4.2.231,232 The dissociation constant is the product of the two individual dissociation 
constants and a factor termed linking coefficient, E.231,232 An ideal linking coefficient would be less 
than 1 and less than optimal or linker resulting in negative cooperativity would give an E value 
greater than 1.232 The THIQ-Monosaccharide was designed with a three-methylene linker in hopes 
of generating a molecule with superadditivity to generate a more potent inhibitor with selectivity 
for CD44 over the other hyaladherins (Figure 4.3). To test the linker design, computational efforts 
in the form of docking and scoring were employed and the conjugate molecule was found to have 
greater computational affinity than either of the individual components. The conjugated THIQ 
molecule was then tested in an SPR assay and was found to not inhibit HA-CD44 interaction. A 
CD44-THIQ-Monosaccharide conjugate co-crystal structure could not be solved using soaking 
techniques which had proved successful for other CD44 structures. To understand the lack of 
binding affinity observed, a conformational search in silico was performed and found that a greater 
than 6 kcal/mol potential energy difference existed between the ideal binding pose as modeled and 
the lowest energy conformation. Docking and scoring efforts were used again to assess the 
computational binding affinity and deviation from ideal binding pose of the THIQ-Disaccharide 
conjugate and 8 related mimetics. Our findings suggest that the 4’-hydroxyl is critical to the 
observed affinity and deletion of the 2’-hydroxyl might impart enough conformational flexibility 
to allow for proper binding of the THIQ and saccharide moieties. While we did not get any 
biophysical or structural biology data on the THIQ-Monosaccharide conjugate, we suggest design 
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and synthesis of the THIQ-GCU-NAG conjugate and the THIQ-d2-OH-GCU-NAG conjugate for 
their improved binding affinity as potential inhibitors of CD44. 
Equation 4.1 Gibbs Free Energy of Binding Derived From Linking Two Molecules 
∆"!" =	∆"! + ∆"" + ∆"# 
Equation 4.2 Dissociation Constant for Linked Molecule 
&$!" = &$!&$"' 
 
Figure 4.3 THIQ-Linked Oligosaccharide Development 
Overlay of 8-amino THIQ (PDBid: 5BZI) with HA-tetrasaccharide (PDBid: 4MRD) both 
bound to mCD44. Interatomic distances between the endocyclic nitrogen of the THIQ and the 
3’ hydroxyl of Glc-5 is 5.3 Ångstroms and the proposed THIQ-monosaccharide conjugate 
shown in the lower left having a distance of 5.1 Å. 
4.2 Methods 
4.2.1 Reagents 
All computational studies were completed using Maestro233 part of the Schrodinger 
Software Suite hosted through the Minnesota Supercomputing Institute (MSI) at the University of 
Minnesota. Full-length human CD44 (hCD44) cDNA and murine CD44 (mCD44) cDNA were a 
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gift of Dr. James B. McCarthy at the University of Minnesota. Rosetta 2(DE3)pLysS cells were 
purchased from EMD Biosciences (Gibbstown, NJ) and competent cells were made by using a Mix 
and Go! E. coli Transformation Kit from Zymo Research (Irvine, CA). HiPrep 16/60 Sephacryl S-
100 HR was obtained from GE Healthcare (Piscataway, NJ). High molecular weight hyaluronan 
(HMW-HA) from rooster comb in the form of sodium salt was purchased from Sigma-Aldrich (St. 
Louis, MO). CM5 and SA Biacore Sensor Chips were acquired from formerly GE Healthcare 
(Piscataway, NJ) now Cytiva. L-Arginine, reduced/oxidized glutathione, coupling reagents, and 
other general buffer reagents were from Sigma-Aldrich (St. Louis, MO). The hydrazide biotin 
linker for biotinylated HA was from Thermo Scientific (Rockford, IL). The crystallography 
supplies including 24 well plates, coverslips and crystal-crushing tools were obtained from 
Hampton Research (Aliso Viejo, CA). 
4.2.2 Protein Preparation Wizard234 in Schrodinger Suite 
 The structure of murine CD44 co-crystallized with a tetrahydropyran linked THIQ, PDBid: 
5bzr227, was used for the computational studies as it contained the pharmacophore of interest in the 
small-molecule binding pocket and extends into the hyaluronan binding groove. The PDB file was 
imported into Maestro233 and the Protein Preparation Wizard234 was employed to ready the model 
for subsequent computational docking. Missing hydrogen atoms were added, co-crystallized waters 
were removed, and missing atoms and residues were added prior to running Prime235, Schrodinger’s 
protein structure predictive program. Finally, a restrained minimization of the structure was 
completed to sample hydrogen atom position and relax strained bond, angles, and clashes.  
4.2.3 Ligand Preparation Using LigPrep236 
 The mono-, di-, tri-, and tetra-saccharide HA molecules were generated from the murine 
complex of CD44 with an HA 4-mer (PDBid: 4mrd) by extracting the saccharide portion and saving 
as the desired lengths. The following ligand preparation was not done on the HA-oligosaccharides 
as the molecules were imported and scored in place instead of a traditional docking and scoring 
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approached detailed below. The THIQ-modified oligosaccharides were made in JLigand237 and 
atomic positions superimposed onto the 8-amino-THIQ in PDBid: 5bzr227 and the saccharide of 
PDBid: 4mrd88. The disaccharide mimetics were generated by deleting specific atoms of the 
previously generated THIQ linked disaccharide molecule. Ligand structures were imported into 
Maestro as .mol2 files and LigPrep was employed to properly prepare ligands for docking in the 
computational studies. The OPLS3 force field was selected for minimization.238 Possible ionization 
states at a target pH of 7.0 ± 2.0 (to mimic physiological pH) were generated using Epik.239 
Tautomers of the structures were not generated for any molecules. Specified chiralities were 
retained and the number of poses per structure were not limited.  
4.2.4 Computational Docking using Glide240 in Maestro  
 Docking in Maestro using Glide240 employs a grid for where docked ligands must bind, but 
to further insure proper atomic positions of the THIQ-moiety relative to previously published 
structures several additional constraints were implemented. To begin, a grid was established that 
was a cubic area surrounding the small molecule in the prepared protein structure. To ensure proper 
docking of the THIQ moiety and the linker leading to the saccharide moiety, positional constraints 
were placed on the endocyclic and exocyclic nitrogen atoms of the THIQ and on the oxygen of the 
linker restraining the atomic positions of the docked molecules to within 1 Å of the reference pose. 
Hydrogen bond acceptors/donors were specified for Val30, Glu41, and His39 of the receptor 
protein based off the previously known hydrogen bonding network. Excluded volume spheres were 
placed in the HABD groove where NaG-4 of the HA 8-mer would bind to aid in placement of Glc-
5 in the groove. A core pattern comparison was used to restrict docking position of the heavy atoms 
of THIQ and the linker with a tolerance of 0.1 Ångstroms. Torsional constraints were placed on the 
carbon linkers of the molecules. For docking of the unmodified HA-oligosaccharides, the additional 
constraints were not used as most of the constraints do not apply to oligosaccharide binding and 
docking could easily replicate atomic coordinates detailed before without the additional constraints. 
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Van der Waals radii were left as their default setting with a scaling factor of 0.8 and partial charge 
cutoff of 0.15. Extra precision (XP) was used with flexible ligand sampling including nitrogen 
inversions and ring conformations. Epik239 state penalties and large excluded volume penalties were 
included to force poses to be closer to expected binding poses. Docking poses were compared to 
the proposed/expected binding pose using RMSD values of heavy atoms in the ligands of interest. 
For more flexible docking of the simplified glucuronic acid disaccharide conjugates, positional and 
torsional constraints and excluded volumes were removed from the generated grid to further sample 
conformational space of target molecules. 
4.2.5 Conformational Search Using Molecular Mechanics 
A conformational search of the THIQ-saccharide conjugates was performed using the 
Conformational Search241 in Maestro. The THIQ pharmacophore was kept fixed and all other 
atoms and angles were allowed to freely move and rotate. An OPLS3238 force field was applied for 
the molecular mechanics calculation and conformations were ranked by their relative potential 
energies. A total of 50 conformational states were generated for each ligand. To compare the 
conformations to the expected binding conformation, rms calculations (atom criteria was changed 
depending on the specific target of the search) were used to find the ideal pose from the various 
conformations. 
4.2.6 Cloning, Expression, and Purification of Human CD44 (hCD44) 
HABD and Murine CD44 (mCD44) HABD 
Soluble and properly folded hyaluronon binding domain of human CD44 (hCD44 HABD) 
was expressed and purified as previously described.88 In short, hCD4420-178 was transformed into 
Rosetta2(DE3)pLyss cells and plated on LB Amp100 Cm30 agar plates. A single colony was 
selected from the overnight incubation and added to a vial containing 5mL of LB Amp100 Cm30 
and allowed to shake overnight at 270 rpm and 37°C. 1L LB media was inoculated with 3 mL of 
the overnight culture and placed in the incubator using the same parameters until mid-log phase 
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(OD600 = 0.6-0.8) was reached. The culture was then rapidly chilled in an ice bath until the 
temperature of the culture was below room temperature prior to induction with 0.4 mM isopropyl-
b-D-thiogalactosidase (IPTG). The culture was induced for 4 hours at 30°C and 270 rpm and then 
the cells were harvested by centrifugation at 5000g for 15 minutes. Resulting cell pellet was stored 
overnight at -20°C. Protein isolation and refolding was completed using previously described 
methods.86 The inclusion bodies were isolated using iterative rounds of washing with TritonX-100 
and use of a Dounce Homogenizer. The pellet was then solubilized at 4°C in an 8 M urea buffer 
overnight. The unfolded protein was added to a refolding buffer containing 250 mM arginine, 2 
mM reduced glutathione, and 1 mM oxidized glutathione using an Econo Gradient Pump for rapid 
dilution to reduce aggregation and allow for proper refolding. The protein was allowed to stir in 
the refolding overnight at 4°C prior to concentrating the protein using an Amicon Stirred-
Ultrafiltration cell to ~5mL. Monomeric hCD44 HABD was isolated from oligomeric forms of the 
protein using a HiPrep 16/60 Sephacryl S-100 column equilibrated with SEC Buffer (20 mM Tris 
pH 8.0 and 150 mM NaCl) and fractions analyzed on an SDS/PAGE gel. To the fractions 
corresponding to monomeric HABD was added 10% glycerol and then flash-frozen before storage 
at -80°C for future use.  
4.2.7 Immobilized-HA Surface Plasmon Resonance Assay 
To confirm the binding affinity a previously published biophysical assay, an immobilized-
HA surface plasmon resonance (SPR) assay, was employed.88 In brief, high molecular weight-HA 
(HMW-HA) was biotinylated using hydrazide biotin as previously described,242 and was 
immobilized onto a streptavidin SA Biacore Sensor Chip using established methods.88 
Biotinylated-HA in a HEPES-EP Buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 
0.005% (v/v) Surfactant P-20) was passed over the streptavidin chip surface until the response 
signal stabilized at 115 RU as monitored with the Biacore S200. The chip surface integrity and the 
competition-based assay were confirmed using a positive control, HA-10, in a two-fold dilution 
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series incubated with a fixed concentration of hCD44 (~17 mM) on a plate shaker for 10 minutes 
at room temperature to allow for binding of the small molecule to hCD44. Samples in a 96-well 
format were placed on the Biacore S200 and injected over the chip surface at 30 µL/min for 1 
minute followed by 2 minutes of a dissociation phase using the same HEPES-EP buffer. Following 
the confirmation of the IC50 value for HA-10, the assay was applied to the THIQ-monosaccharide 
conjugate solubilized in DMSO. The same SPR experimental parameters used for HA-10 were 
employed. Values taken 5 seconds prior to the end of the association phase were used in subsequent 
analysis. 
4.2.8 Attempted Co-crystallization of mCD44 with THIQ-
Monosaccharide Conjugate 
Crystallization of mCD44 was reproduced using previously published conditions.85,88 
mCD44 frozen at -80°C was thawed on ice prior to concentrating to 8 mg/mL. Protein was mixed 
in a 1:1 ratio with well solution containing 30% PEG MME 5000, 200 mM Na2SO4 and 100 mM 
MES pH 6.5. Monoclinic form crystals grew in about 4 days as polymorphic plates and were used 
in subsequent rounds of seeding to yield separate plate-like crystals. Apo mCD44 HABD crystals 
were transferred to a drop containing well solution supplemented with 10% glycerol and THIQ-
monosaccharide conjugate at 10 mM. Crystals were allowed to soak for a variable period from 5 
minutes to 1 hour prior to being flash frozen in liquid nitrogen and ready for data collection. 
4.2.9 X-Ray Data Collection and Structural Determination 
X-ray diffraction data was collected at IMCA-CAT beamline 17-ID at the Advanced 
Photon Source (APS), Argonne, Illinois, USA. Collection was conducted at 100 K using 1.00 
Ångstroms wavelength radiation on a Dectris Eiger2 9M detector. Data was processed using 
autoProc and aP_scale using R-factor (<.4), completeness (>.9) and I/sigma (>2) as criteria, with 
a minimum of two of the three criteria being met to determine the proper resolution range.201 The 
mCD44 model with a bound THIQ-tetrahydropyran molecule (PDBid: 5bzr227) was used as the 
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search model in molecular replacement with Phaser.202 The monoclinic crystal in space group P21 
was found to contain two protein chains in the asymmetric unit, as previously described, and 
iterative rounds of refinement and model building were carried out using Phenix203 and Coot204,243. 
The THIQ-Monosaccharide conjugate was not found in any of the structures solved and therefore 
coordinates and associated reflection data are not included in this chapter. 
4.3 Results and Discussion 
4.3.1 Increasing Length of HA-Oligosaccharides Exhibit Improved 
Docking Scores 
 Previous biophysical efforts have shown that increasing length of HA-oligosaccharides 
(HA-4 to HA-12) exhibit greater binding affinity and inhibitory potential.88 The smallest HA-
oligosaccharide that could be quantified in the two SPR assays was HA-4.88 Our initial 
computational efforts sought to quantify the binding affinity of the HA-oligosaccharides as a means 
of better understanding the binding modality of each increasing saccharide unit and to replicate the 
poses of previously published structures.85,88 We focused on the HA-oligosaccharides binding 
between Glc-5 and NaG-8 in the hyaluronan binding domain groove as our THIQ-saccharide 
conjugates extend towards this portion of the groove. Our docking studies were able to replicate 
the hydrogen bonding network of previous crystallographic data which proves that our 
computational methods are an accurate measurement tool given the current model (Figure 4.4) 
Binding of the docked tetrasaccharide is stabilized through hydrogen bonds with 7 different amino 
acids within the HA-binding groove. The NaG-8 is slightly rotated relative to the crystal structure 
of mCD44 with the tetrasaccharide but is still able to engage in the hydrogen bond. Docking scores 
increase (a more negative number – further away from 0) with each increasing saccharide unit 
added. We see the largest relative change in docking scores moving from the monosaccharide to 
the disaccharide (-2.886 vs. -4.699) and little increase moving from the trisaccharide to the 
tetrasaccharide (-5.849 vs. -5.965), (Table 4.2). It has been well established that HA makes weak 
interactions within the binding groove but that NaG-6, through the N-acetyl functional group, is 
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able to form hydrogen bonds with Ile100 and Tyr46 which explains the large increase in docking 
scores moving from the monosaccharide to the disaccharide. NaG-8 is able to make one additional 
hydrogen bond with Tyr109 but the entropic cost of binding could explain the relatively small 
improvement in docking scores. Further inhibitor design should attempt to target the sites occupied 
by NaG-6 and Glc-7 as these sites play a key role in the affinity of hyaluronan for the binding 
groove. 
Table 4.2 Docking Scores of HA-Oligosaccharides and THIQ-Saccharide Conjugates 
Compound Docking Score 




THIQ-Monosaccharide Conjugate -6.441 
THIQ-Disaccharide Conjugate -8.083 





Figure 4.4 Hydrogen Bond Comparison Between Docking and Published Structures 
A) Monosaccharide, B) Disaccharide, C) Trisaccharide, and D) Tetrasaccharide in cyan as the 





























4.3.2 Docking Studies Suggest that THIQ-Saccharide Conjugates will 
have Higher Binding Affinity 
Following the determination that docking scores improved with increasing length of HA-
oligosaccharides, the THIQ-saccharide conjugates were tested. Initially, the ligands were tested 
using the same parameters for docking in Glide, but the poses generated were deemed poor as the 
location of the THIQ pharmacophore was not found in the small-molecule subsite of mCD44 and 
was not making any of the known key interactions. Therefore, to force the docking poses to 
resemble the proposed binding pose more closely, by keeping the positioning of the THIQ and 
saccharide moiety intact, positional, torsional, and excluded volume constraints were imposed 
(Figure 4.5). With the constraints in place, the number of plausible binding modalities was 
decreased and therefore only a select number of docked poses had to be analyzed. The small number 
of resulting poses were compared to the proposed conformation using rms calculations. The 
docking scores of the preferred binding poses were analyzed and as the length of the THIQ-
saccharide conjugate is increased there is a proportional increase in the docking scores (Table 4.2). 
While the docking of the saccharide molecules and the THIQ-saccharide molecules use different 
constraints to obtain the docking poses and scores, the scores can be compared as the same force 
field, OPLS3 is applied to all the molecules. The docking scores for the conjugates are all greater 
(more negative) than the individual saccharide molecules and therefore conjugation of the two 
molecules creates tighter binding as expected by linking two fragment molecules. The molecules 
are able to branch the two binding subsites and allow for binding of both the THIQ-pharmacophore 
and proper placement of the saccharide unit within the hyaluronan binding domain (Figure 4.6). 
This supports the three-methylene linker design linking N2 of 8-amino-THIQ to the 3’-hydroxyl of 
Glc-5. The docking studies suggest that synthesis of the disaccharide and trisaccharide molecules 





Figure 4.5 THIQ-Saccharide Conjugate Docking with CD44 
mCD44 shown in the white cartoon and surface with the bound THIQ-monosaccharide 
conjugate in blue surrounded by a blue surface. The three structures (THIQ-monosaccharide, 
THIQ-disaccharide, and THIQ-trisaccharide conjugates) shown with their chemical structures 
and their docked poses in green sticks docked with mCD44.  
 
Figure 4.6 Docked THIQ-Monosaccharide Maps Onto HA-Tetrasaccharide 
THIQ-Monosaccharide (cyan) docked into mCD44 (PDBid: 5bzr) places the saccharide portion 

















































4.3.3 THIQ-Monosaccharide Shows No Inhibitory Potential in the 
Immobilized-HA SPR Assay and Could Not Be Soaked into Apo 
mCD44 Crystals 
 With the knowledge that the THIQ-saccharide conjugates should have increased binding 
affinity over the unmodified saccharides, the THIQ-Monosaccharide was synthesized by Dr. Soma 
Maitra in Dr. Gunda Georg’s lab. Synthesis involves a 7-step process with a reductive amination 
to link the 8-amino-THIQ to a protected Glucuronic acid and was incredibly challenging and took 
an extensive time to complete (Scheme 4.1). The THIQ-Monosaccharide conjugate was tested 
using the immobilized-HA SPR assay to determine the inhibitory potential and crystallization 
attempted to determine the binding modality and key interactions between the molecule and 
receptor. The immobilized-HA SPR was selected of the two established SPR assays in the Finzel 
laboratory as the goal of the project was able to selectively block HA binding to CD44 and thus 
causes inhibition of downstream signaling of CD44 in cancer metastasis and progression. The 
assay, which is competition-based (small-molecules that bind to the HABD of CD44 block CD44 
from binding to the HMW-HA chip surface), was confirmed with the positive control, HA-10 (an 
oligosaccharide of HA containing 5 repeating units of monomeric HA). The IC50 of HA-10 was 
calculated to be 32 µM which aligned with the previously published value of 48 µM. With the 
functionality of the assay confirmed, THIQ-Monosaccharide was tested and found to not inhibit 
binding of CD44 to the chip surface as the RU level for each sensorgram, regardless of 
concentration of THIQ-Monosaccharide, did not change (Figure 4.7). Although an IC50 value could 
not be determined, an attempt was made to co-crystallize mCD44 with the THIQ-Monosaccharide 
to confirm the integrity of mCD44 and attempt to learn about the binding modality of the THIQ-
Monosaccharide conjugate.  The 1.84 Ångstrom resolution structure shows the protein adopts the 
correct tertiary structure (Figure 4.8A). Apo mCD44 crystals were soaked in a solution containing 
10 mM THIQ-Monosaccharide for varying length of time, but even at the longest soaking duration 
(1 hour) the presence of the small molecule is not detected in the electron density (Figure 4.8B). 
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While not definitively conclusive, the inability to quantify an IC50 or generate a co-crystal complex 
leads us to reason that the THIQ-Monosaccharide conjugate  
does not bind to CD44. 
 
Scheme 4.1 Synthesis of THIQ-Monosaccharide Conjugate 
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Figure 4.8 Attempted Co-Crystallization of THIQ-Monosaccharide with mCD44 
A) Tertiary structure of mCD44 shown in salmon with the protein surface shown in white at 1.84 
Ångstrom resolution. B) Electron density shown in blue shown of mCD44 showing soaking 











4.3.4 6 kcal/mol Energy Difference Observed in Conformation Search 
in vacuo Between Ideal Binding Conformation and Lowest 
Energy Conformation 
Following the negative results in the immobilized-HA SPR assay and the soaking 
approaches to generate a co-crystal complex of mCD44 with the THIQ-Monosaccharide conjugate, 
computational efforts were once again employed to sample possible conformations of the small 
molecule to explain the lack of affinity observed. The THIQ-Monosaccharide conjugate was 
designed based on the results of the THIQ-tetrahydropyran which exhibited weak affinity but was 
able to bridge the small molecule binding site with the hyaluronan binding groove.227 The three-
carbon linker was selected as it gave the correct distance between the two pharmacophores (THIQ 
and Glc-5) and allowed the flexibility for proper binding of each component. A plausible 
explanation for the lack of binding affinity is that the lowest energy conformation of the THIQ-
Monosaccharide was energetically further away from the ideal binding pose and that the free energy 
of binding was lower than this barrier. To sample the conformational poses in space, molecular 
mechanics or molecular dynamics can be used.244,245 Molecular dynamics accounts for the 
molecular behavior in a solvated space as a function of time, but it requires a large computational 
effort and therefore molecular mechanics was selected.244,245 A simple molecular mechanics 
calculation is doing a conformational search in vacuo which finds all energetically favored 
conformations by finding local minima on the energy curve by sampling all torsion angles of a 
given molecule.241 The results of the conformational search found that the difference between the 
lowest energy conformation and the ideal binding conformation was approximately 6 kcal/mol 
(Figure 4.9). While these results do not properly simulate how the compound would behave in 
solution or in the presence of the protein, it points to the idea that potentially the binding energy is 
lower than the amount of energy required for the molecule to adopt the ideal binding pose and 




Figure 4.9 Conformational Search of THIQ-Monosaccharide Conjugates 
A) 50 conformations generated by the conformational search with the THIQ moiety 
superimposed. B) Bar graph of OPLS3 Potential Energy vs the different conformations. The 






























4.3.5 Simplification of Glucuronic Acid Allows NaG-6 to Dock Closer 
to Proposed Binding Site 
Previous docking and scoring efforts had afforded that binding affinity should increase 
with increasing length of the saccharide conjugates. Since binding affinity and a co-crystal complex 
were not observed for the THIQ-Monosaccharide conjugate, computational efforts were employed 
on the THIQ-Disaccharide conjugate to guide inhibitor design. The NaG-6 binding site of the HA 
binding groove makes increased hydrogen bonds with NaG-6 of HA-oligosaccharides as exhibited 
in PDBids: 4mrd and 2jcq. The THIQ-Disaccharide conjugate and 8 mimetics of the conjugate 
based on deletion of functional groups around Glc-5 were examined to determine the effect of these 
deletions on steric hindrance/flexibility of the conjugates to allow for optimal binding position of 
NaG-6 (Figure 4.10). The molecules containing a deletion have the prefix “-d” followed by the 
functional group which has been removed in the given mimetic. The reason that the THIQ-
Monosaccharide conjugate might not bind is that steric hindrance disfavors the postulated binding 
pose and therefore simplification should increase affinity. Initially, molecular mechanics were 
employed again in the form of a conformational search of the conjugate and associated mimetics, 
but the approach was abandoned as there were large difference in potential energy associated with 
nearly identical conformations. Therefore, docking and scoring using Glide was used with 
increased binding flexibility to better sample binding conformations. The same Xtra Precision 
Flexible Docking was employed on the same structure (PDBid: 5bzr) with hydrogen bonding 
constraints on Val30 and Glu41 with no other positional or torsional constraints. 10 conformations 
for each ligand were tested and then analyzed for the ability to properly dock the NaG-6 in the 
correct spot by rms calculations. A visual representation of the workflow for the process can be 
seen in Figure 4.11. Compounds that exhibit a large RMSD value are unlikely to bind and therefore 
can be removed from further consideration even though THIQ-d4-OH-Glc-NaG has the best 
docking score of any of the mimetics tested (Table 4.3). The majority of compounds then removed 
from further consideration all have the same removal of the hydroxyl group on position 4 of 
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glucuronic acid which necessitates this modification on any future inhibitor design to increase 
binding affinity and assure proper conformation. Of the remaining molecules two of are particular 
interest. The unmodified THIQ-Glc-NaG compound exhibits the best docking score which should 
hopefully translate into greater binding affinity. The other molecule of interest is THIQ-d2-OH-
Glc-NaG as it has the lowest observed deviation from the ideal binding pose. Removal of the 2’ 
prime hydroxyl could increase flexibility and allow for the correct positioning of the NaG-6 moiety. 
 




































































































































































































































































































































Figure 4.11 Workflow of Docking and Scoring of THIQ-Disaccharide Conjugate 
Mimetics 
Ligands of interest were docked and scored using Glide with 10 conformations of each ligand. 
Ligands were compared to the ideal binding pose by using RMSD calculations based on the 
location of the NaG-6 portion of the conjugates.  
 
Table 4.3 Comparison of Docking Scores and RMSD Values of Preferred Binding Poses of 
THIQ-Disaccharide Conjugate Mimetics 
Compound RMSD Docking Score 
THIQ-Glc-NaG 0.811 -7.725 
THIQ-cHexyl 5.192 -7.096 
THIQ-d(ALL)-Glc-NaG 0.695 -6.217 
THIQ-d(4-OH-5-COOH)-Glc-NaG 1.825 -5.911 
THIQ-d(2-OH-5-COOH)-Glc-NaG 0.638 -6.046 
THIQ-d(2,4-OH)-Glc-NaG 0.620 -6.165 
THIQ-d5-COOH-Glc-NaG 0.755 -7.088 
THIQ-d4-OH-Glc-NaG 4.741 -8.033 






Computational efforts were employed to guide synthesis and design of THIQ-saccharide 
conjugates. Initial efforts in docking of the saccharide units found that increasing saccharide length 
increases the relative docking score which follows the trend of the HA-oligosaccharides previously 
tested.88 The largest change in docking scores was observed when moving from the monosaccharide 
to the disaccharide which is supported by previous crystallographic efforts and the hydrogen 
bonding network observed in the NaG-6 binding site of the HA-binding groove. The THIQ-
saccharide conjugates were subsequently docked and scored with increased constraints that could 
be described as scoring in place instead of traditional docking and scoring. The THIQ-saccharide 
conjugates had better docking scores than the unconjugated saccharides with the same trend of 
increasing saccharide length of the conjugates increasing the relative docking score being observed. 
Docking scores suggest that synthesis of the disaccharide conjugate and trisaccharide conjugate 
should yield higher potency than the monosaccharide conjugate. The THIQ-Monosaccharide was 
found to exhibit no inhibition of CD44-HA interaction in the immobilized-HA SPR assay, and also 
a co-crystal structure of THIQ-Monosaccharide conjugate with mCD44 via soaking was 
unsuccessful. The results taken in parallel mean that the THIQ-Monosaccharide makes weak to no 
interaction with CD44. To explain the absence of binding, a conformational search in vacuo of the 
THIQ-Monosaccharide was performed which found a difference of 6 kcal/mol in potential energy 
between the ideal conformation and the lowest energy conformation. Flexible docking on the 
THIQ-Disaccharide conjugate found that the 4’ prime hydroxyl is critical to placement of NaG-6 
and that deletion of the 2’ prime hydroxyl affords extra flexibility to adopt the ideal conformation. 
Future work should include synthesis of the THIQ-Disaccharide conjugate and assessment of the 






5. Biophysical Approaches to Assess Binding Affinity 
and Binding Modality of Verbascoside and CD44 
 
 
Portion of this chapter have been excerpted from published works. 
 
Scheme 5.1 was used with permission from: Hartmann, M.; Parra, L. M.; Ruschel, A.; Linder, C.; 
Morrison, H.; Herrlich, A.; Herrlich, P. Inside-out Regulation of Ectodomain Cleavage of Cluster-




A detailed background on the HABD of CD44 including the crystal structure bound to an HA-




Glioblastoma (GBM) is the most lethal primary brain tumor with a 3-5% 5-year survival 
rate.246 General treatment for GBM includes surgery to remove majority of the tumor followed by 
radiation and/or chemotherapy.247 This treatment protocol is ineffective in the majority of patients 
as 98% of patients will suffer from GBM reoccurrence and tolerance to radiation and 
chemotherapy.248 A group of stem cell-like cells called glioblastoma stem cells (GSC) are 
considered to be mainly responsible to GBM reoccurrence and resistance to chemotherapy and 
radiation treatments.249  
CD44 is a transmembrane glycoprotein that is a marker of GSCs and is over-expressed in 
a variety of tumor cells that interacts with both polymeric hyaluroan (HA) and fragments of 
HA.249,250 Other than HA, substrates of CD44 include hepatocyte growth factor (HGF) and 
osteopontin.251,252 Osteopontin triggers an increase in cell proliferation by causing the release of the 
intracellular domain through g-secretase and localizes in the cytoplasm and nucleus with other 
transcription factors.252,253 Interaction with osteopontin and HA is dependent on CD44 dimerization 
through disulfide bonds formation.254 Inhibition of CD44 dimerization could therefore be an effect 
tumor therapeutic strategy. 
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Verbascoside or acetoside, as it also known, is a phenylethanoid glycoside that was first 
isolated from mullein but is also found in several other plant 
species among which is Plantago pysillium (Figure 5.1).255,256 
Verbascoside has been widely used in traditional Chinese 
medicine practices as it has various pharmacological activities 
including antioxidant, antimicrobial, anti-inflammatory, 
neuroprotective, and wound healing effects along with 
antiproliferative effects in cancer.255,257 A recent study by 
Wang and colleagues has found that verbascoside can block CD44 dimerization and therefore act 
as an anti-glioma antigen through inhibition of the CD44 signaling pathway.104 Monomers and 
dimers of CD44 exist on the cell surface, and dimers are stabilized by cysteine bonds within the 
intracellular domain (ICD) and the transmembrane domain of CD44 (Scheme 5.1).254 Ser291 can 
then be dephosphorylated in the dimer complex allowing for binding of phosphorylated ERM 
proteins that displace merlin causing a restrictive conformation of the CD44 ICD which can be 
cleaved by g-secretase.84,253 The intracellular domain is then involved in a variety of downstream 
signaling pathways including the PI3K/AKT pathway contributing to cancer cell invasion and 
proliferation and the MAPK signaling pathway leading to cancer cell division and 
proliferation.254,258,259 
Using systemsDock and a mouse CD44 (mCD44) structure of the hyaluronon binding 
domain (2JQC) in computational modeling, verbascoside was predicted to have a higher potential 
binding affinity than the native ligand, HA.85,104,260 Models also predict that verbascoside can make 
molecular interactions through HABD residues Ala103, Tyr109, Leu111, and Val112. These amino 
acids are highly conserved between hCD44 and mCD44.85,104 Using an MST in vitro assay, 
verbascoside was found to have a lower half-maximal effective concentration (EC50) than 
verbascoside and osteopontin.104 HEK293 cells-transfected with CD44-YNE/CD44-YCE were 
used in a biomolecular fluorescence complementation (BiFC) assay to quantify the effect of 
 


















verbascoside on CD44 dimerization.104 Verbascoside was found to decrease dimerization in a dose-
dependent fashion.104 U251MG cells treated with 60 µM verbascoside had lower levels of the 
cleaved CD44 ICD thus showing inhibition of the CD44 signaling cascade.104 Finally using a 
xenograft mouse model, verbascoside was found to cause a reduction in tumor growth and 
prolonged survival suggesting that verbascoside may be an effective treatment of mouse GBM.104 
 
Scheme 5.1 CD44 Cleavage Regulation by Dimerization 
 Our work with verbascoside sought to further understand the molecular interactions of 
CD44 with verbascoside to guide future inhibitor design aimed at increasing selectivity and 
potency. Verbascoside is postulated to interact with the hyaluronan binding groove of CD44 HABD 
based upon computational methods, but no structural or biophysical data supported this binding 
modality. The Finzel laboratory has successfully characterized the binding affinity, inhibition and 
structure of a series of small molecules and HA-oligosaccharides and these tools can be employed 
to confirm that verbascoside actually interacts with the CD44 HABD. We applied three biophysical 
assays to gain an understanding of the molecular interactions. These findings were intended to be 
used along with crystallographic data of the co-crystallized complex to support or refute the binding 
modality observed in Wang and colleagues computational docking studies. Verbascoside was 
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found to cause a small destabilization of CD44 HABD using differential scanning fluorimetry, but 
neither of the surface plasmon resonance assays were able to provide evidence of a direct 
interaction between verbascoside and the HABD of CD44. 
5.2 Experimental 
5.2.1 Reagents 
Full-length human CD44 (hCD44) cDNA was a gift of Dr. James B. McCarthy at the 
University of Minnesota. Rosetta 2(DE3)pLysS cells were purchased from EMD Biosciences 
(Gibbstown, NJ) and competent cells were made using a Mix and Go! E. coli Transformation Kit 
from Zymo Research (Irvine, CA). HiPrep 16/60 Sephacryl S-100 HR was obtained from GE 
Healthcare (Piscataway, NJ). High molecular weight hyaluronan (HMW-HA) sodium salt from 
rooster comb was acquired from Sigma-Aldrich (St. Louis, MO). CM5 and SA Biacore Sensor 
Chips were purchased from GE Healthcare (Piscataway, NJ). L-Arginine, reduced/oxidized 
glutathione, coupling reagents, and other general buffer reagents were from Sigma-Aldrich (St. 
Louis, MO). Hydrazide biotin linker for making biotinylated HA and PCR Plates (96-well, low 
profile, non-skirted, white) for DSF experiments were from Thermo Scientific (Rockford, IL). 
5.2.2 Expression and Purification of hCD44 
hCD44 and mCD44 HABD was cloned, expressed, and purified as previously described in 
Chapter 4.88 
5.2.3 Differential Scanning Fluorimetry 
Differential scanning fluorimetry experiments were conducted on a BioRad CFX96 Well 
System (Hercules, CA) using 96-well PCR plates and previously published protocols.208. To 
determine the optimal protein concentration for use in the DSF experiment, a scan was completed 
on a two-fold dilution series of hCD44 HABD (0.5-0.01 mg/mL). To the wells was added protein 
at varying concentration, Sypro-Orange (1:500 dilution of 5000x), and DSF Buffer (20 mM Tris 
pH 8.0 and 150 mM NaCl) to a final volume of 40µL. The DSF scan was completed using 0.5°C 
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steps (25-80°C) while holding for 30 seconds at each temperature increment. The resulting 
fluorescence curves were fitted using a Boltzmann model for non-linear regression in the curve 
fitting software: Bio-Rad CFX 2.0.209,210 A concentration of 0.1 mg/mL was used for subsequent 
experiments using the least amount of protein while still getting a robust fluorescence signal. To 
determine the effect of verbascoside on protein stability, several concentrations of verbascoside (5-
0.625 mM), solubilized in the SEC buffer, were added to the well components described above and 
tested in triplicate. Effect on protein stability was calculated by taking the denaturation temperature 
of hCD44 in the presence of verbascoside and subtracting that by the denaturation temperature of 
apo hCD44. 
5.2.4 Immobilized CD44 HABD SPR Assay 
Determination of verbascoside binding affinity for hCD44 HABD was performed on an 
immobilized hCD44 HABD surface using Surface Plasmon Resonance (SPR) on a Biacore S200 
(GE Healthcare) as previously described.88 A CM5 Biacore Sensor Chip was activated with 0.4 M 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 0.1 M N-hydroxysuccinimide 
prior to flowing hCD44, that had been dialyzed against 10 mM MES pH 4.4 overnight, until a 3500 
Response Units (RU) level was achieved. The remaining reactive carboxymethyl groups were 
blocked with 1 M ethanolamine. Verbascoside in a PBS buffer containing 0.005% Surfactant P-20 
was passed over the chip via a two-fold dilution series (10 mM – 78 µM) at 30 µL/min for 60 
seconds. Bound verbascoside was dissociated from the chip surface using the same running buffer 
over 60 seconds at 30 µL/min to return the chip back to initial baseline. RU values were plotted 




5.2.5 Immobilized High molecular weight hyaluronan (HMW-HA) SPR 
Assay 
A competition-based HA-binding assay was performed to determine the inhibitory 
potential of verbascoside using SPR on a Biacore S200 (GE Healthcare). HMW-HA sodium salt 
from rooster comb was biotinylated using hydrazide biotin and immobilized onto a SA Biacore 
Sensor chip using previously published methods.88,242 In brief, biotinylated HMW-HA was flowed 
over the streptavidin chip surface until the response signal stabilized at 115 RU as monitored with 
the Biacore S200. For the competition-based assay, a fixed concentration of hCD44 HABD (~17 
µM) was incubated for 10 minutes on a plate shaker at room temperature with a two-fold dilution 
series of verbascoside (10 mM – 78 µM) in HEPES-EP buffer. CD44-verbascoside mixtures were 
passed over the immobilized HMW-HA chip surface at 30 µL/min for 60 seconds followed by 2 
minutes of a dissociation phase using HEPES-EP buffer. Levels of CD44 bound to the chip surface 
were determined by taking the RU level at 5 seconds before the end of the association phase.  
5.3 Results and Discussion 
5.3.1 Verbascoside Causes Small Shift in hCD44 Denaturation 
Temperature 
Differential scanning fluorimetry (DSF) experiments were conducted as a fast and 
inexpensive experiment to assess the effect of the small-molecule on protein folding and stability. 
The Tm, melting temperature, is the point where the amount of native folded protein is equal to that 
of the denatured or unfolded protein. A Tm for hCD44 in the absence of a small-molecule was 
calculated to be 45.7°C which is slightly higher than previously published results (45°C), but it 
confirms that the protein is properly folded and behaving similarly.227 The Tm is not as important 
as changes in the Tm upon ligand binding that correlate with the effect of binding on stability of the 
protein of interest. The highest concentration of verbascoside caused a 1.7°C decrease in the 
unfolding temperature of the protein (Figure 5.2A). In drug discovery and fragment screening using 
DSF, generally, positive shifting molecules are prioritized.214 A negative shifting ligand may have 
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a destabilizing effect on the tertiary structure of the protein, or stabilize a non-native state of the 
protein. Several researchers have published negative shifting ligands/fragments that have preceded 
successes in their medicinal chemistry campaigns.261–263 Verbascoside was tested at five different 
concentrations in a two-fold dose response and the change in thermal stability was found to be 
proportional to the concentration of verbascoside present (Figure 5.2B). This same trend follows 
previous observations of stabilizing compounds.264–266 1.7°C is a relatively small shift, but 




Figure 5.2 Verbascoside Effect on hCD44 Protein Stability 
A) First-derivative plot of fluorescence versus temperature with apo protein shown in blue and 
protein + verbascoside (5 mM) in red. B) Dose response on protein stability versus varying 
concentration of verbascoside. Standard deviation for the melting temperatures are shown with 
the black error bars for a dataset of N=8. 
5.3.2 Verbascoside Binds Weakly to CD44 HABD 
To determine the binding affinity, KD, of verbascoside for hCD44 HABD, a previously 
published immobilized HABD SPR assay was performed.88 To confirm the integrity of the chip 



















































tested and the resulting KD value aligned with previously published values. Verbascoside in a two-
fold dilution series was flowed over the chip surface and the small-molecule caused a change in the 
refractive index which can be quantified as an increase in the response units. Increasing 
concentration of verbascoside causes a higher response denoting that more small-molecule is bound 
to the chip surface (Figure 5.3). For determination of the KD, RU values taken 5 seconds prior to 
the end of the association phase were used and plotted in GraphPad Prism. The software gives a 
projected KD of 24.9 mM (the term projected is applied as the value is higher than the highest 
concentration tested in the experiment). The published solubility in water or DMSO of verbascoside 
is 100 mg/mL (~160 mM) and to reach saturation in the SPR assay 10x the KD needs to be tested 
and this concentration (~250 mM) is not possible to reach in solution. Increasing the concentrations 
tested in the assay could help get a better estimate of the KD, but the binding affinity is still low. 
An odd phenomenon observed in these spectrographs is the high RU signals which is equal 
to the amount of bound analyte in each experiment. In the assay as the concentration of 
verbascoside is increased, the RU signal also increases and does not reach a saturation level. The 
most logical explanation for this occurrence is that verbascoside binds with a stoichiometry greater 
than 1:1. The maximum RU is given in Equation 5.1 and is dependent on the amount of ligand 
(hCD44 bound to the chip surface), the molecular weight of the ligand and the analyte 
(verbascoside), and the stoichiometry of binding.267 An initial stoichiometry of binding of 1:1 was 
used in calculations as that is the ratio that was assumed in the virtual screen.104 Entering implicit 
values into Equation 5.1 (Rmax is the maximal RU signal, Rligand is the amount of immobilized ligand, 
Mr is the molecular weight, and Vligand is stoichiometry of binding), the maximal RU for the 
experiment should be approximately equal to 124 RU. The stoichiometry of binding, according to 
the 10 mM sensorgram of verbascoside (RU = 660), is at least 1:5 (protein:analyte) which means 
there are multiple spots on the protein that verbascoside is able to interact with more than one site 
on CD44 HABD. Crystallographic efforts with mCD44 have shown that the HABD groove can 
accommodate up to an 8 saccharide units.85 Verbascoside or caffeoyl phenylethanoid glycoside 
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containing a disaccharide of β-ethyl-O-α-L-rhamnopyranosyl-β-D-glucopyranoside would mimic 
a dually modified HA-dimer and therefore it is possible that the groove could accommodate more 
than one molecule of verbascoside. In the assay, verbascoside interacts with hCD44 but orthogonal 
assays and structural biology efforts are needed to understand the binding modality and the number 
of binding sites on hCD44 HABD that can interact with verbascoside. 
 
Equation 5.1 Maximum Theoretical RU for a Given Ligand and Analyte 





Figure 5.3 Sensorgram of Verbascoside in Immobilized HABD SPR Assay 
5.3.3 Verbascoside Does Not Decrease Bound hCD44 HABD in a 
Competition SPR Assay 
 Since an accurate determination of the KD was not obtained, an orthogonal approach to 
quantify the binding interaction of verbascoside with hCD44, a previously established 
immobilized-HA SPR competition assay, was employed.88 Various protein concentrations were 
flowed over the chip surface to establish a dose-dependent effect on the RU signal observed that 
reflects CD44 HABD binding to the chip surface and confirms the immobilization of HMW-HA 
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hCD44 will inhibit binding of its natural substrate, HMW-HA (the active chip surface), so a 
decrease in binding of hCD44 to the surface will be observed relative to apo protein. To test the 
competitive inhibition, an HA-oligosaccharide, HA-10, was used as a positive control. HA-10 was 
incubated with the protein prior to being flowed over the chip surface and inhibits binding of CD44 
to the chip surface at increasing concentration of HA-10. An IC50 value, which can be calculated 
from the resulting sensorgram data, of 32 µM was obtained, which aligns well with previously 
published data.  
With the assay working, verbascoside was tested in a two-fold dose-response assay. The 
sensorgrams shows that verbascoside at the highest concentrations tested appear to decrease the 
amount of CD44 bound to the chip surface (Figure 5.4A). The highest concentration of 
verbascoside (10 mM) has a negative sensorgram; the RU level is less than the initial baseline 
signal, which means that the analyte is interacting more strongly or non-specifically with the 
reference chip surface containing unmodified streptavidin than it is with the active chip surface. 
SPR experiments detect binding levels for an analyte and ligand of interest relative to the analyte 
only binding levels. SPR chips consists of lanes and an experiment consists of injecting the same 
sample over two lanes: one the active chip surface with an immobilized ligand (Biotinylated HMW-
HA in this experiment) and the other the reference chip surface which does not have immobilized 
ligand (streptavidin only). The sensorgrams in Figure 5.4A are the result of taking the sensorgram 
corresponding to the analyte effect on the active chip surface and subtracting the sensorgram of the 
analyte over the reference chip surface. The subtraction step should, for the most extent, remove 
any effects of buffer mismatch (analyte conditions do not align with running buffer), fluidic effects, 
and non-specific binding that occurs in both the reference and active surface, and therefore, allow 
for analysis of the isolated effect of the analyte interacting with the ligand. Upon closer examination 
of the binding to the reference chip surface, a tool included within the Biacore Evaluation Software, 
verbascoside at increasing concentration interacts more strongly with the reference chip surface 
(Figure 5.4B).268 The Biacore Software determines the reference binding levels by comparing the 
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RU levels of the reference chip surface relative to the lowest concentration of analyte tested (any 
change in buffer or flowing a small molecule will cause a change in the refractive index regardless 
if it interacts or not). The lowest concentration of analyte is set at zero for the reference binding 
level and if molecules interact more strongly with the reference chip surface this change in RU is 
quantified as the binding reference level. For accurate biophysical interpretation and analysis, the 
analyte should interact consistently with the reference chip surface regardless of concentration. 
Since verbascoside is interacting with the reference chip surface, an additional mathematical step 
was taken to attempt to understand the effect of verbascoside on the inhibition of CD44. The 
reference binding levels (described above and shown in Figure 5.4B) were added to the RU levels 
taken 5 seconds prior to the end of the association phase in the sensorgrams below (Figure 5.4A). 
This mathematical manipulation of the data should remove the non-specific interactions on the 
reference chip surface and isolate CD44 interaction with the immobilized-HA surface as caused by 
verbascoside concentration. The majority of the two-fold dose-response (78.125-1250 µM) is 
relatively flat (no decrease in bound hCD44) but there is a slight decrease in RU at the highest 
concentrations tested (Figure 5.4B). Due to the shape of the curve (follows a more linear fit than 








Figure 5.4 Verbascoside Immobilized-HA SPR Assay Results 
A)  Sensorgram of verbascoside in the immobilized-HA SPR assay with the legend shown below 
the graph. B) Scatterplot of binding level (green), binding to the reference chip surface (blue), 
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Verbascoside was tested using two biophysical techniques in a total of three different 
assays: differential scanning fluorimetry, an immobilized-HABD surface plasmon resonance assay, 
and an immobilized-HA surface plasmon resonance. Verbascoside was found to nominally 
decrease the protein unfolding temperature of hCD44 relative to apo protein, likely by binding to 
and stabilizing a non-native (or partially unfolded) state of the protein. To further quantify and 
qualify verbascoside interaction with hCD44, two surface plasmon resonance assays were 
employed to determine the binding affinity, KD, and inhibitory potential, IC50. Verbascoside caused 
an increase in RU level that was proportional to the amount of analyte flowed over the chip surface. 
While a KD of approximately 25 mM can be projected, an accurate KD could not be determined as 
the projected KD was greater than the highest concentration tested in the assay. Solubility issues 
with verbascoside make an accurate determination of the KD not possible. The RU values observed 
at the highest concentration were greater than the calculated maximum RU leading to a conclusion 
that verbascoside and CD44 may not interact with a 1:1 stoichiometry. Further investigation is 
needed to support this notion. Finally, verbascoside was tested in the immobilized-HA SPR assay 
to determine the IC50 value. Verbascoside interacted in a dose-dependent manner with the reference 
chip surface, where no HMW-HA has been immobilized. Taking into account the non-specific 
interaction with the reference chip surface, it was found that only at the highest concentrations of 
verbascoside tested was there a slight decrease in the amount of bound hCD44. Through our 
biophysical studies we were not able to gain further insight and understanding into the interaction 
between verbascoside and hCD44. Our findings show weak CD44-verbascoside interactions in two 
of the assays tested which does not disprove or support the findings published by Wang and 






6. A Novel Surface Plasmon Resonance Assay and 





Kunli Liu in Dr. Xuefei Huang’s laboratory at Michigan State University completed the synthesis 
of the modified-HA molecules. The synthesis of these molecules is not discussed in detail but the 
resulting compounds are used in this study. The ELISA experiment and data analysis was 
completed by Kunli Liu and permission was given to include the data in this chapter. 
 
 
An in-depth look at the extracellular matrix in cancer, the signaling molecule HA, the family of 
hyaldherins, the HA-binding protein CD44, and the structure of the HABD and its interaction with 




Hyaluronan (HA), repeating units of glucuronic acid (Glc) and N-acetyl glucosamine 
(NaG), is an integral component of the extracellular matrix (ECM) where it provides structural and 
functional integrity to cells and tissues.89 High concentrations of HA are needed in many organs to 
provide structural framework and space filling for cells to migrate.63 To shape the molecular 
environment in which they live, cells must orchestrate a balance between production and turnover 
of HA with roughly one-third of the total body HA concentration being replaced daily.269–271 
Polymeric-HA (1,000 to 10,000 kDa) is catabolized to fragments (10 to 100 kDa) that can be 
recycled into newly synthesized HA.89,90 Certain pathological conditions such as cancer causes an 
increase in the turnover of HA where these fragments of HA serve as signaling molecules in the 
matrix91,270,272 and have been linked to cell differentiation72, angiogenesis73,91, tumorigenesis74,75, 
and resistance to cancer chemotherapy269,273. 
CD44 is of the family of hyaluronan-binding proteins, hyaladherins, that has been 
discussed extensively in the previous two chapters (Chapter 4 and Chapter 5) and in the introduction 
chapter (Chapter 1).77 Previous structural data has shown that CD44 is a challenging drug target. 
The murine CD44 HABD (mCD44) complex with an HA oligosaccharide has an extended HA 
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binding site (surface area greater than 800 Å2) with molecular binding stabilized by many weak 
interactions with at least seven consecutive saccharide units of HA.85 The protein-polysaccharide 
complex resembles protein-protein interactions that have been a difficult target for medicinal 
chemists to disrupt with small-molecules. Structural biology and biophysical fragment screening 
in the Finzel laboratory resulted in the discovery of an inducible small-molecule subsite near the 
hyaluronan binding groove.88,227 One approach to potentially target this challenging target is linking 
a small-molecule with known affinity for CD44 to an oligosaccharide of HA as a means of 
increasing binding affinity over HA and imparting selectivity for CD44 over the other proteins of 
the family of hyaladherins (extensively described in Chapter 4). Another approach for targeting 
CD44 is by modifying full-length HA to screen for conjugate molecules with larger binding affinity 
and inhibitory potential relative to the unmodified HA. 
To target the hyaluronan binding domain of CD44, Dr. Xuefei Wang and Kunli Liu at 
Michigan State University designed a series of modified-HA molecules using an Ugi reaction.274 
The Ugi reaction is a four-component reaction that requires carboxylic acid-, amine-, aldehyde-, 
and isocyanide-containing reagents.275 The glucuronic acid (Glc) portion of HA contains a 
carboxylic acid moiety that can be modified with different amine, aldehyde, and isocyanide 
combinations to generate a library of HA derivatives (Scheme 6.1).274 The Ugi reaction does not 
modify every carboxylic acid and therefore the loading percentage, or ratio of modified to 
unmodified carboxylic acid moieties, can be determined by comparison of the unmodified full-
length HA (FL-HA) to the modified HA using nuclear magnetic resonance (NMR).274 Polymeric 
HA is the composite of many different lengths of HA and the Ugi reaction can occur with varying 
frequency and pattern therefore resulting in a diverse and varied population of modified HA 
molecules: molecules within a given sample are not the same. The library of modified HA 
molecules was then tested using a competitive ELISA assay with CD44 and two other hyaladherins, 
LYVE-1 and HARE, to determine binding affinity relative to the unmodified native substrate, HA, 
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in hopes of finding a modification that has increased affinity over HA and binds tighter to CD44 
than the other hyaladherins to generate a selective molecule (Table 6.1).274 The results of the ELISA 
found that the aldehyde 2, formaldehyde, is probably the privileged aldehyde for the HA derivatives 
and amines E, F, G, I, and K (where F, G, I, and K are all aromatic containing amines) are the 
tightest binders of CD44.274 The ELISA assay did not quantitative binding and therefore the team 
at Michigan State reached out to the Finzel laboratory to employ our published surface plasmon 
resonance (SPR) assays to quantify the KD and IC50 values of a series of modified-HA molecules. 
Three modifications at different loading percentages were sent to the Finzel laboratory for 
biophysical characterization and comparison of the effect of loading percentage on binding affinity 
and inhibition potential. The three modifications that were selected for analysis were A2a, F2a, and 
G2a (Table 6.2). Both F2a and G2a exhibit increased and comparable binding affinity for CD44 as 
calculated by the ELISA assay: 38%±1%, and 38%±0%, respectively. A2a on the other hand has 
lower affinity for CD44 than the natural substrate, HA (-14%±6%). The two modifications with 
improved binding affinity were selected to confirm the binding affinity in an orthogonal assay and 
to assess any difference in the two modifications with respect to their effects on CD44. The A2a 
modification was selected as it could be used as a control compound to show a compound that binds 
with lower affinity for CD44. The three modifications all have the same aldehyde, carboxylic acid, 
and isocyanide reagents and therefore the contribution of the specific amines can be assessed. Initial 
concern of these molecules was that an accurate binding affinity could not be determined as the 
starting material, HA, is a distribution of species with a mean molecular weight and the loading 
percentages are variable between compounds in the library. We therefore sought to compare the 
relative response of HA and the modified-HA molecules at the same fixed running concentration 
(µg/mL) to determine the relative binding affinity and the relative inhibitory potential in two SPR 
assays: an immobilized HABD SPR assay and an immobilized-HA SPR assay. Due to the 
polymeric nature of the molecules, we encountered flow and avidity issues which made 
determining the binding affinity impossible. We developed a ligand reference subtracted SPR assay 
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which decreased the noise of the polymeric ligands thus allowing a clearer assessment of the effects 
of the modified-HA molecules on CD44-HA interaction. We observed a decrease in the inhibitory 
potential with increasing loading percentage which is contradictory to traditional small-molecule 
inhibition (more small-molecule equals greater inhibition) and therefore developed a probability 
function to explain this relative decrease. Our formula and known structural biology work suggest 
that CD44 HABD is only able to accommodate one modification per 8 saccharide units (the length 
which the HABD groove can accommodate) and with higher loading percentage we observe a 
higher likelihood of smaller distances between modifications.  
 
 
Scheme 6.1 Ugi Reaction to Modify Glucuronic Acid of HA 
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Table 6.1 ELISA Data for Modified-HA Molecules Against Three Hyaladherins 
 
If inhibition difference is positive, the HA derivatives have enhanced affinity toward the 
hyaladherin tested (red highlighting) and if it is negative, it has decreased affinity (green 
highlighting). N.D. represents the data is not available. Compounds were tested against: CD44, 
LYVE-1, and HARE (data down the column).  
40%±0% -14%±6% -13%±6% -10%±0% -13%±4%
41%±0 -7%±1% 3%±3% N.D. 11%±0%
N.D. 5%±5% N.D. N.D. N.D
-8%±0% 3%±11% -9%±7% -14%±6% -11%±0%
N.D. N.D. N.D. 8%±0% 7%±2%
5%3±2% N.D. -9%±3% N.D. 3%±10%
N.D. 23%±14% 34%±5% N.D. N.D
N.D. 23%±1% 24%±3% N.D. N.D
N.D. 12%±7% N.D. N.D. N.D
-10%±2% 2%±0% -6%±1% -23%±3% -18%±3%
N.D. N.D. N.D. 2%±2% 3%±1%
5%±11% 4%±1% N.D. -3%±8% N.D
-7%±1% 11%±1% 0%±1% -17%±0% -15%±0%
N.D. 4%±1% N.D. 6%±6% 11%±2%
N.D. -3%±3% N.D. -2%±4% 0%±0%
1%±1% 38%±1% 1%±2% -6%±2% -8%±1%
N.D. 30%±1% N.D. N.D. N.D
11%±2% -5%±3% -4%±2% N.D. -2%±3%
4%±1% 38%±0% -6%±0% 4%±2% -5%±2%
N.D. 22%±0% N.D. N.D. N.D
0%±0% 5%±2% -4%±1% 21%±5% 0%±2%
-13%±5% -26%±2% -7%±1% -23%±0% -10%±0%
6%±1% 8%±0% N.D. 12%±2% 13%±1%
N.D. 3%±4% -2%±1% -2%±7% -4%±3%
9%±1% 22%±0% -1%±1% 4%±6% -8%±1%
28%±0% 11%±1% N.D. N.D. N.D
12%±4% 0%±8% -10%±1% 15%±3% 14%±3%
30%±2% 23%±1% 3%±1% -22%±4% -25%±3%
32%±0% 4%±1% N.D. 19%±4% 5%±2%
N.D. 7%±3% 9%±2% 13%±7% 8%±3%
8%±1% 36%±0% 29%±1% -18%±5% 20%±1%
35%±1% 33%±1% 27%±0% N.D. 33%±1%
30%±0% 24%±2% N.D. N.D. N.D










































Table 6.2 Structure (R-Group) of Modified-HA Molecules 
Molecule Structure (R group) 
Relative Inhibition Difference as 












6.2.1 Reagents  
Full-length human CD44 (hCD44) cDNA was a gift of Dr. James B. McCarthy at the 
University of Minnesota (Minneapolis, MN). Rosetta 2(DE3)pLysS competent cells were 
purchased from EMD Biosciences (Gibbstown, NJ). HiPrep 16/60 Sephacryl S-100 HR was 
obtained from GE Healthcare (Piscataway, NJ). High molecular weight hyaluronan (HMW-HA) 
sodium salt from rooster comb was obtained from Sigma-Aldrich (St. Louis, MO). CM5 and SA 
Biacore Sensor Chips were obtained from GE Healthcare (Piscataway, NJ). L-Arginine, 
reduced/oxidized glutathione, coupling reagents, and other general buffer reagents were from 
Sigma-Aldrich (St. Louis, MO). Hydrazide biotin linker for making biotinylated HA was from 
Thermo Scientific (Rockford, IL). 
6.2.2 hCD44 HABD Cloning, Expression and Purification 












6.2.3 Immobilized hCD44 HABD SPR Assay 
Molecular affinity for the hCD44 HABD was assessed by monitoring binding to a surface 
with covalently immobilized hCD44 HABD using Surface Plasmon Resonance (SPR) on a Biacore 
S200 (GE Healthcare) as previously described.88 In short, a CM5 Biacore Sensor Chip surface was 
activated with 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 0.1 M N-
hydroxysuccinimide. hCD44 HABD dialyzed against 10 mM MES pH 4.4 was flowed over the 
surface and bound via amine coupling until saturation at 3500 Response Units (RU) was achieved. 
Remaining carboxymethyl groups were blocked with 1 M ethanolamine. To quantify binding of 
molecules of interest, full-length HA (FL-HA) and HA-derivatives in a PBS buffer containing 
0.005% Surfactant P-20 were passed over the chip surface in a two-fold dilution series (2.5 mg/mL 
– 19.5 µg/mL) at 30 µL/min. Equilibrium response units were measured after 60 seconds. Initial 
dissociation periods were set for 60 seconds but increased to 180 seconds to attempt to return 
binding levels back to baseline when slow dissociation was observed.  
6.2.4 Immobilized HA SPR Assay with Ligand Only Binding 
Subtraction 
HMW-HA was biotinylated using hydrazide biotin as previously described,242 and 
immobilized onto a streptavidin SA Biacore Sensor Chip using established methods.88 In short, 
biotinylated-HA in HEPES-EP was passed over the chip surface until the response signal stabilized 
at 115 RU as monitored with the Biacore S200 (GE Healthcare).  For the competition-based assay, 
a fixed concentration of hCD44 HABD (~17 µM) was incubated with serial dilutions (2.5 mg/mL 
– 19.5 µM) of ligands (FL-HA and HA-derivatives) solubilized in HEPES-EP and placed on a plate 
shaker for 10 minutes at room temperature prior to placing samples on the Biacore S200. Mixtures 
were injected over the chip surface at 30 µL/min for 1 minute followed by 2 minutes of a 
dissociation phase using HEPES-EP buffer. RU values taken 5 seconds prior to the end of the 
equilibrium phase were plotted against concentration to calculate IC50 values. Data was fitted using 
a nonlinear regression with log[inhibitor] vs. response using GraphPad Prism.218  Issues 
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surrounding non-specific binding, binding to reference chip surface, and fluidics problems of the 
polymeric molecules complicated analysis. 
A reference subtraction experiment was completed to decrease fluidic problems and non-
specific interactions associated with the polymeric nature of FL-HA and HA-derivatives. Ligand 
only was passed over the chip surface using the same two-fold dilution series maintaining the same 
buffer and experimental conditions and the resulting sensorgram was subtracted from the resulting 
sensorgram of CD44 preincubated with ligand. A graphical representation of the reference 




Scheme 6.2 Ligand Reference Subtracted Surface Plasmon Resonance Assay 
A) Graphical representation of the reference subtraction by subtracting the effects of free ligand in solution from hCD44 HABD incubated with 





6.2.5 Probability Function to Assess Distance Between Modifications 
Equation 6.1 shows the probability of finding a given distance between modifications 
within the HA-derivatives. The equation makes the following assumptions: 1) That all molecules 
of HA in solution are of the same length, 2) Steric hindrance or intramolecular interactions do not 
impact the location of modifications, 3) The probability of finding a modification on any given 
glucuronic acid is equal to the loading percentage, and 4) The formula is a function of D, the 
distance between glucuronic acid monomer units. If D is 1 there is only one N-acetyl glucosamine 
between each modification. 
 
Definition of variables used in Equation 6.1: 
L = number of glucuronic acids in a given length of HA 
LP = loading percentage 
M = number of modifications = L x LP 
Dmax = maximum distance modifications = L-M+1 
D = distance between modifications 
P (D) = probability of finding a particular distance between modifications 
N = integer of possibilities from 1 to M-1 
6.3 Results and Discussion 
SPR has been used previously to characterize binding involving the CD44 HABD in two 
different ways88: the Immobilized hCD44 HABD Assay has proved an effective tool for measuring 
the affinity (KD) of small molecules for the HABD, while the Immobilized HA Assay has been 
used to quantify the binding of the CD44 HABD to a surface coated with HA.  When that CD44 
!(#) = 	'( × *





Equation 6.1 Probability Function of Distances Between Modifications 
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HABD is preincubated with antagonists that compete for binding with HA, the latter assay has been 
used to observe a reduction in CD44 HABD association to the HA surface.  By observing dose-
dependent responses to this competition, an IC50 (the concentration at which 50% of the binding of 
CD44 to the surface is eliminated) can be determined.  It was hoped that one of these methods could 
be applicable in assessing the effect of chemical modifications to polymeric HA on CD44 HABD 
binding.   
6.3.1 Inability to Quantify Binding Affinity in Immobilized HABD SPR 
Assay 
Since all modified HA analogs are created by chemical modification of FL-HA, we first 
sought to characterize its affinity for the hCD44 HABD using the Immobilized hCD44 HABD SPR 
assay.  In this assay, the ligand (e.g., FL-HA) is flowed over a surface coated with hCD44 HABD, 
and the mass change upon binding triggers the resonance effect measured in response units (RUs). 
This assay has been successfully applied to determine KD of binding of both small molecule 
fragments, and short oligosaccharides with affinity for hCD44 HABD88. To confirm surface chip 
integrity, positive control, HA-10 (an HA 10-mer), was passed over the chip surface in a two-fold 
dilution series (250 µM – 1.95 µM). FL-HA, and in fact all the HA-derivatives (not shown) behaves 
very differently than small molecules in this assay, likely due to fluidic properties arising from the 
polymeric nature of FL-HA and the potential for high avidity with multiple (but unnumbered) sites 
for interaction with immobilized HABD.   FL-HA was slow to reach equilibrium binding, 
particularly at low concentration, and washed off the surface even more slowly (Figure 6.1).  
Moreover, very high binding to the unmodified dextran surface of the CM5 chip was observed in 
instrument reference channels that further complicated data analysis. Taken together, these factors 




Figure 6.1 Spectrograph of FL-HA in the Immobilized hCD44 SPR assay 
Spectrograph shows a non-plateau during the equilibrium phase and slow dissociation phase that 



















6.3.2 Use of Reference Subtracted SPR Sensorgrams to Accurately 
Determine Effects of Modified-HA on CD44 
Attempts to exploit the Immobilized HA assay exposed similar problems. In this assay, 
hCD44 HABD is flowed over an HA coated surface to which it binds, and a reduction in surface 
response can be observed when the HABD is preincubated with antagonists that inhibit binding 
through its interactions with the HABD. To determine the integrity of the chip surface various 
concentrations of hCD44 (0-150 µM) in HEPES-EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 
3 mM EDTA, 0.005% (v/v) Surfactant P-20) were passed over the HMW-HA surface. An apparent 
KD can be calculated for the affinity of hCD44 to the chip surface and previous work has shown 
that small molecules can specifically affect the apparent KD.88 Small molecules are able to compete 
off HMW-HA and this decrease in hCD44 interaction with the chip surface can be used to calculate 
the IC50 of specific small molecules. To confirm this competition, a positive control, HA-10 in a 
two-fold dilution series (250 µM – 1.95 µM) was incubated with a fixed concentration of hCD44 
(~17 µM) and an IC50 value of 32 µM was determined for HA-10 that was close to previously 
published value of 48 µM. Upon introducing the polymeric FL-HA to the flow, the same problems 
with fluid control, binding kinetics, reference surface affinity and avidity arise to complicate both 
data collection and analysis. 
Table 6.3 Loading Percentage of Modified-HA Compounds Calculated by NMR 











Preliminary experiments with the HA coated surface clearly revealed differences in binding 
effects of FL-HA and some of its derivatives, so a reference subtraction strategy was devised to 
mask these effects while isolating CD44 binding. Three unique modifications to FL-HA (A2a, F2a, 
and G2a) at two different loading percentages dependent on the amount of aldehyde present in the 
Ugi reaction (25%: 1:1:0.25:1 (acid:amine:aldehyde:isocynanide) and 50%: 1:1:0.5:1) were tested 
in the Immobilized HA assay (Table 6.3). For simplicity the molecules will be referred to using the 
following syntax: Modification_aldehyde ratio (e.g., A2a_25%). The loading percentage, amount 
of modified glucuronic acids, as calculated by SPR is shown in Table 6.3. For FL-HA and each of 
the derivatives, a complete set of sensorgrams were collected for both a two-fold dilution series 
without any hCD44 HABD, and an identical series including preincubation with hCD44 (~17 µM).  
Reference subtracted sensorgrams reflecting CD44 binding to the surface were generated by 
subtracting curves obtained for the ligand only from those that included CD44, and IC50 values 
were computed from each reference-subtracted concentration series. A relative percent inhibition 
calculated by taking the IC50 of FL-HA and dividing it by the corresponding IC50 value of the HA-
derivatives was calculated for comparison (Figure 6.1). The inhibition percentage of FL-HA is set 
at 100% and compounds observing a relative inhibition percentage greater than 100% bind tighter 
to hCD44 HABD than FL-HA. F2a-25% and G2a-25% were found to have greater inhibitory 
potential than FL-HA as they bind tighter to the HABD while A2a-25% was found to have lower 
inhibitory potential as shown in Figure 6.2. These results align well with the data from the ELISA 




Figure 6.2 Relative Percent Inhibition of CD44 
Relative inhibition of each compound at the labeled loading percentage calculated by dividing 
the calculated IC50 value of FL-HA by the IC50 of the modified compounds. Compounds with 
greater inhibitory potential have a relative percent inhibition greater than 100%. 100% inhibition 
is denoted with the dashed line. The error bars depict the SD of the observations collected (N=3). 
6.3.3 Probability Function to Explain Effect of Loading Percentage on 
Inhibitory Potential 
The percent inhibition was measured for A2a, F2a and G2a with samples prepared with 2 different 
loading percentages. While results with A2a-50% confirm that this analog has little effect on 
binding, both F2a and G2a show a decreased percent inhibition with higher loading percentage. 
This result was somewhat unexpected.  If something binds, then more of something might be 
expected to bind better.  An explanation of this may lie in statistics, however. Previous structure 
biology work has shown that the CD44 HABD is able to accommodate four repeating units of N-
acetyl glucosamine and glucuronic acid (the monomeric units of FL-HA) within an extended 








































binding groove.85 A plausible explanation for the decreased affinity at higher loading percentage is 
that the groove is only able to accommodate at most a single modification at a time. To assess the 
difference in binding affinity observed as a result of loading percentage a probability formula was 
employed. The formula is able to calculate the likelihood of finding a specific distance between 
modifications, D, where D equal to 1 would mean there is one N-acetyl glucosamine between 
modifications. The formula relies on the following assumptions: 1. All molecules of FL-HA are the 
same length; 2. Steric hindrance and intramolecular interactions do not impact the locations of 
modifications (Substitutent incorporation is truly random); 3. The probability that a specific 
glucuronic acid moiety is modified is equal to the loading percentage. Taking the sum of the 
probabilities of D > 4 will give the percentage of modifications that would lie further apart than the 
length of the extended binding groove of CD44 HABD for a given length of HA. Multiplying the 
number of modifications, which is equal to the product of length and loading percentage, by the 
percent of modifications that occur when D>4 will give the number of modifications that occur 
greater than 8 saccharide units apart. Figure 6.3 depicts the effects of loading percentage on the 
number of modifications that occur greater than D=4 and the effect of loading percentage on 
relative percent inhibition. Fitting the scatterplot of number of modifications that lie greater than 8 
saccharide units apart with a polynomial curve fitting and solving the equation to find the local 




Figure 6.3 Effect of Loading Percentage on Percent Inhibition of HA-Derivatives Relative 
to Unmodified FL-HA 
The left axis shows relative percent inhibition of hCD44 HABD. The bar on the left represents 
F2_25% and that on the right shows F2a_50%. The righthand axis represents the number of 
modifications that occur greater than 8 saccharide units apart. The smooth-line scatter plot 
represents the effects of loading percentage on the number of modifications occurring greater 
than 8 saccharide units apart. 
6.4 Conclusion 
As suspected, an accurate binding affinity, KD, could not be determined due to the inability 
to quantify the molar concentrations of the modified-HA molecules and the flow and avidity issues 
encountered due to the polymeric nature of HA. Similar issues with flow were observed in the 
immobilized-HA SPR assay, but through the implementation of a ligand reference subtraction step 
(flowing ligand in the absence of protein over the chip surface and subtracting the resulting 
sensorgrams from the ligand plus protein sensorgrams) the noise related to flow could be decreased 
thus allowing for proper analysis of the effects of the molecules on CD44-HA interaction. Our 
results confirmed the ELISA data generated at Michigan State University in an orthogonal assay, 


































































F2a Percent Inhibition Modifications Occuring Greater Than 8 Saccharide Units Apart
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but we were able to build upon their findings by determining the effects of loading percentage on 
inhibition. As the loading percentage is increased, the associated inhibitory potential decreases 
which is contradictory to traditional small-molecule inhibition. By generating a probability function 
for the distance between modifications dependent on the loading percentage and length of HA, an 
optimal loading percentage was determined. The HABD may only be able to accommodate one 
modification within the groove and more than one modification within the groove causes a decrease 
in the relative inhibitory potential. Our studies suggest that an optimal loading percentage of 19% 
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